patient_fhir_id,unique_drugs,drug_count,total_orders,duration_days
e-52xp4YZd1f97qcoSIWWc9amYQ44t8jvTTPV.mda8G43,Temozolomide capsule; Valproic Acid; bevacizumab; etoposide; irinotecan; temozolomide,6,118,342
e-9vcBJ6AnN50ExKNrHsTfo3OMLfxwEoCsTBgEDDRLgM3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,998,188
e-AF.x-KMG2Nq6m6j-e.VIBsKYwZAhDDkmFtUq-eZsAg3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,14,144,269
e-EmpJ5Emdu3wscBx24Weee2Yxt.jOFEKdgkl4n6wV743,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; tretinoin; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",118,266,1436
e-RTlNNtrnYfazO7K4JGWzQUSogJpql1w3CHWg1pCsnk3,Cyclophosphamid; Cyclophosphamide; Investigational Chemotherapy (unspecified); Leucovorin; carboplatin; cisplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; isotretinoin; mesna; methotrexate; pegfilgrastim; tretinoin; triamcinolone,17,219,3192
e-S7KrYx4anss4mGG3oiHHg3,leuprolide,1,1,0
e-VC0NdGf7NQ8MG7wwsxkosmAikP2dHAIHfBwqS.Yw9U3,Progesterone; carboplatin; vincristine,3,34,971
e-fnAlV.Hdotudq5VM1JmzA3,bevacizumab,1,26,203
e-gFkg1siEmG99J.k2Wvfyw3,Testosterone Cypionate,1,11,2467
e-hgJTfX4d-M2xcve6NsC6K.WxNu7ytCDJ8zBA2g9hTo3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; vincristine,15,104,130
e-i3fQ6-8QBVoig3pSqyXcsacHC0TcJyp3iGrxHeOkek3,Progesterone; Valproic Acid,2,14,3750
e-lgWluWmMAV3nvzUpF2PkgBEokIF2-U1DiJOVPFnwk83,propranolol,1,7,73
e-occdUBdaqlfUyBzvNkE8k9EDhUKLm-DO53JHAdgJhI3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Rituxan; cytarabine; doxorubicin; filgrastim; methotrexate; pegfilgrastim; rituximab; vincristine,11,98,83
e-rO8NyjjwlpT8wsnZ2yIuA3,ATRA,1,1,0
e.0GSZYtNymOwqjRIHluFSA3,Sufentanil,1,1,0
e.41HS7aZONnShOFHB4CHXn5yyEba6fI0HDu9RnLRla83,anastrozole; letrozole,2,3,305
e.FLRy2KdM0038QEnvL51g29vT9D5F7-whd32C8l7HYI3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,99,96
e.Fp4JbVwSkPO3wPOz6kDekzg9-4vrj80w.R-0aIsUcg3,carboplatin; tretinoin; vincristine,3,59,449
e.GTtyxlbPoAOfpRj8yTu0AyZYUCccQG8bPCmADnNSR83,Cyclophosphamid; Cyclophosphamide; Neulasta; Ziextenzo; cisplatin; filgrastim; pegfilgrastim; vincristine,8,84,223
e.JuENJGFtX.VodJU0RqRvLqhlNQwAP0LsQLTl-Hcp3I3,Lupron Depot; carboplatin; leuprolide; leuprolide acetate; triamcinolone; vincristine,6,530,683
e.P3P3a-rlbhPOdRVNNDZ1g3,ATRA; Apatinib; Avastin; Temozolomide capsule; bevacizumab; lapatinib; lapatinib ditosylate; temozolomide,8,155,2794
e.RtN7E1ndCosIwVDx4E8jFsLOUj8hVJALpw0.1p058Y3,vincristine,1,12,41
e.Xw9pO2wPQwIP4ysO-djJnBM19NnaSPKgSVuvxloJc03,Progesterone,1,1,0
e.ZkfR0RM.0kVQ7MiiY3tbmmBpe2tWQF4EI12EwacHKQ3,ATRA,1,1,0
e.kShlCkXQ9cb-w6l1wNvP4bGCKpAIBt22GEB2EdDvNA3,Ketoconazole; carboplatin; vincristine,3,607,419
e.llcR8PtBGmiznMnYGtUBik3ngrJmXXyDlYxg.WkORY3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,552,32
e.n1.kFChMsIk9cnFIGKoIz6.B9XJe6SHsjRokdRsCA03,G-CSF; GM-CSF; aldesleukin; filgrastim; isotretinoin; tretinoin,6,42,181
e.sMs85wuQ78ftNW6qJhWSw3,Lupron Depot; Vinblastin; Vinblastine Sulfate; Zofran; leuprolide; vinblastine,6,18,791
e00FLabseLWmHR35zc0erqNMlYGelM9EGI1WWOq-HTQ43,Progesterone,1,2,584
e095AMfHirrVBzLnfVG2Rm7tjXWV3xO.O4xMZjKuumjs3,Fulphila; IMPACT; Valproic Acid; carboplatin; etoposide; filgrastim; pegfilgrastim; vincristine,8,51,747
e0AbGHmhM-ovEPG6Fm33OPmpcTXo9u-K3p4lRSNte7LQ3,Progesterone,1,4,720
e0D.i0qNuKJlw.UfknqhRbOjDc4VMfC38XGyFXBhW4JM3,triamcinolone,1,1,0
e0HUcmlqz5ftAP9Dx.PfrTibp84O20D0UKoveOEBJz2E3,Progesterone,1,2,350
e0JArwCYW3PcVfOcvOGsp8GYq2Zy1.RnujiVDmp9Bd8s3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,78,97
e0X4W67PH.4csxgf.5zC9HQ3,Zofran; bevacizumab; carboplatin; irinotecan; vincristine,5,16,27
e0dM8C7f52bkgz-h3I29eqns3o-OXEiQu-WLAHzJop3s3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Valproic Acid; cisplatin; etoposide; filgrastim; mesna; vincristine,10,94,73
e0fIHvaBfm2NjycDRlqbFDlo1LWBwW8StDiuFT9FF3uM3,Cyclophosphamid; Cyclophosphamide; G-CSF; Temozolomide capsule; cisplatin; etoposide; filgrastim; gemcitabine; mesna; pegfilgrastim; pemetrexed; plerixafor; temozolomide; vincristine,14,156,825
e0h9wMrVcLNLtzNztwRcF4EbX0qw4qnBpAbzcxDL.Xmk3,vincristine,1,12,33
e0m2EGZqw83N2lb3vfRu9SyQOGJwcgqTXg6oPPHgM2PM3,bevacizumab; etoposide; topotecan; triamcinolone,4,26,967
e0nidWjjVXFPPFrmZDKeLBELJhiP3eAaTDsfIRaxfXfI3,Dabrafenib Mesylate; Dimethyl Sulfoxide; Koselugo; carboplatin; dabrafenib; selumetinib; trametinib; trametinib dimethyl sulfoxide; triamcinolone; vincristine,10,152,1720
e0nvO47R4UmXDdPHvLN90hjqS4I9TsuparMZhc13WGe83,Cyclophosphamid; Cyclophosphamide; Neulasta; Valproic Acid; amifostine; cisplatin; filgrastim; gemcitabine; mesna; pegfilgrastim; pemetrexed; vincristine,12,118,195
e0uQIbZZrhWXaKKJE8aQsdImX4DyvzZvg31rPh8CXe.o3,ATRA; carboplatin; vincristine,3,13,182
e0zHIoWe-fOovB3izoPTjzOBiyTsuNpK9NRv0vH7Vp5w3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Infliximab; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; tretinoin; vincristine,15,132,1082
e137B3prbANuT4MUDepRC2DFJH7PkgrLpoV0qqaOnXgc3,Progesterone; Temozolomide capsule; carboplatin; filgrastim; pegfilgrastim; temozolomide; vincristine,7,30,310
e170ng30t0X77pgAIyoTyuMMArt0DGXZONU3u61OpZXQ3,Dabrafenib Mesylate; carboplatin; dabrafenib; trametinib; vincristine,5,134,2673
e17wPSCZPZalWWUCej4IVIzj0rZnY8kW9Qke4N.g8.BY3,Cyclophosphamid; Cyclophosphamide; Emend; Ketoconazole; cisplatin; lomustine; triamcinolone; vincristine,8,110,4665
e1DNR4czDvfhq4zIAYjDLjlWCjZ6RpUtsj87BgyoG1KA3,Cyclophosphamid; Cyclophosphamide; Dabrafenib Mesylate; G-CSF; Investigational Chemotherapy (unspecified); Mekinist; Tafinlar; dabrafenib; filgrastim; mesna; trametinib; triamcinolone; vincristine,13,48,218
e1J94-9l62xIKTuQ-TC44ow3,ATRA; Cyclophosphamid; Cyclophosphamide; G-CSF; Valproic Acid; filgrastim; mesna,7,37,3393
e1LojU3BqgF8STMOvnBfMfMjaIZDOlXVuMI2teDBKMIc3,Valproic Acid,1,2,0
e1OYkt2AyD7eLufVlqJirk7soLdEZo4uMC.zcyJgkn0w3,vincristine,1,8,21
e1QwSZjjDxLDHe6yyisC1HS1aYSIDQLWw7ShAsf01Tl43,Acetic Acid; triamcinolone,2,9,3978
e1XlERuo1qt5AtBb8gwUACw0Nu9b.8FwVIxTW4XwJV-M3,ATRA; Cyclophosphamid; Cyclophosphamide; Emend; Leucovorin; Valproic Acid; Vinorelbine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; irinotecan; mesna; methotrexate; pegfilgrastim; sirolimus; temozolomide; temsirolimus; topotecan; triamcinolone; vincristine,23,572,1064
e1Z0.TTG4VvXy0uZEyg3syw3,Testosterone Cypionate; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; zoledronic acid,8,60,3868
e1a3dRY04iGWgier3JHBjcA3,Zofran,1,1,0
e1pW0bZ1kdenLTewwtpuDn3HfHy-KcSNzDwwmLJHNvpA3,carboplatin; vincristine,2,140,420
e2.l7h2WGNVYnRz6yMliUCebDnfIQx1Rh3cqZHgEtzCc3,Fulphila; carboplatin; etoposide; filgrastim; pegfilgrastim; triamcinolone; vincristine,7,53,154
e20Jhl7aNcrFltX3GEsGC7g3,Cyclophosphamid; Cyclophosphamide; Lupron Depot; Mitoxantrone; Octreotide; Vinblastin; Vinblastine Sulfate; azacitidine; busulfan; cytarabine; defibrotide; dexrazoxane; lenalidomide; leuprolide; lomustine; mesna; methotrexate; procarbazine; romiplostim; thioguanine; thiotepa; vinblastine; vincristine,23,96,1844
e23rOndg6bStdH.rjjfHKy-XWyAP6Y.DO5N4-y27RPyI3,Temozolomide capsule; Valproic Acid; etoposide; lomustine; temozolomide,5,18,266
e2TPOo9qdPtxF7GGXI8s7sHAiNpgFKAjBce3MmZVY6A83,dexrazoxane; doxorubicin; filgrastim; ifosfamide; mesna; pegfilgrastim,6,78,151
e2Ukwrr2UEil1c1xLtqat.kzOET3bN9eqp.k2A4QwScI3,Ketoconazole; triamcinolone,2,5,453
e2VTBvmJbhnCAT-K3I1FAFJFffxZ23Nc1aS3QNy0ChN03,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,10,246,219
e2Yl4rmKK1UEImWwazYVytQRmihau9-vUlGklQbBtU8Y3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Nivestym; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; vincristine,16,141,158
e2c02-R9ca0HrvIGpDDwx45RRPdtug7qGDM-a.M38SD43,Testosterone Cypionate; lanreotide acetate,2,14,156
e2g-iDJwYy8Hk0v3zvXmmTX97jTx-R3Oxf7nQvjjmb-U3,carboplatin; etoposide; filgrastim; pegfilgrastim,4,34,74
e2ktm5IvJsolbBz5WGvgMHQ3,Ketoconazole; Progesterone; triamcinolone,3,4,1142
e2mqXK7fqHBV78sbXZ.I8FRu1pZwjnQO257uGysuQCgQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",112,3450,1959
e2qf6XdM6TPeVIiJJqH3I9KPfodcSyygjbwOvGlcbIz03,Valproic Acid,1,1,0
e2t37QP4PwzYy.ZTTYODTE3hn9XTeHmxBIL.ylvTlR6g3,Ketoconazole,1,1,0
e2ujmn783D2qP8q0teCbaaeLmeMCnT-0pvy6oXEDwObU3,Zofran; cisplatin; lomustine; vincristine,4,93,391
e2wFH5SmD18se3byVVeGqTw3,sirolimus,1,3,378
e2xrQ.lTgScDPbEd-wnJhPA3,Zofran; carboplatin; trametinib; triamcinolone; vincristine,5,155,2814
e2y8-ImvDIoH-BXP3xxOQbA3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Kisqali; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Tabrecta; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; capmatinib; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; ribociclib; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; topotecan; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",118,390,444
e2zDN7mBw8CoInrBhBPZKKMlwPQzF6d4K6rDBaNNTdqk3,Cyclophosphamid; Cyclophosphamide; Fulphila; Leucovorin; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; temozolomide; topotecan; triamcinolone; vincristine,18,271,572
e2zcyXMZhv4g4p6ErcgE0llEffgNdHLLEq6clhG2kOuM3,cabergoline,1,9,316
e3.ETtKtNTYq.rtaqq3TnqiZTHhZqfWb96FKbAw8KX843,triamcinolone,1,1,0
e33Tye5b5A0Ym4aW5lMqPuQlsd1ucyBU.HUHrNpuR58E3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Valproic Acid; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lenalidomide; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; ritonavir; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",118,852,2970
e35AhEztmnuLLdLtYtoWhVw3,Zofran; carboplatin; vincristine,3,77,1326
e35eGOjr4qMYSQjuR6mInTw3,Temozolomide capsule; temozolomide,2,17,363
e381n3ktd0VVnsYbEkbO40RDA2qqWc32HgbYuVBq7iuc3,Mekinist,1,1,0
e3ASUutGLaPmLlkB.rj9TMMm25mVz9y.4PGT1RvxBUhQ3,Cyclophosphamid; Cyclophosphamide; Neulasta; cisplatin; filgrastim; pegfilgrastim; vincristine,7,96,238
e3RpiPMgQXAYrlhiIzIFlpXVapL26FKaOMtPdu6CvgOQ3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib,5,14,99
e3SMffwjwWoC2-58yF1q7ibHL1Xvjky9zozdgILfZwTs3,Cyclophosphamid; Cyclophosphamide; carboplatin; etoposide; filgrastim; pegfilgrastim; vincristine,7,83,156
e3V22aqnhmi.6SgNy5deTV4xJcpvRI.owoRiei4RKbe83,carboplatin; vincristine,2,16,105
e3Vl4ndhhA.367nH-WoXqzJ2gJkG1y.IoS3qGQX1ceQw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; Glutamine; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; anastrozole; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thiotepa; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vincristine; vorinostat",125,1920,4384
e3bGxPOemEsf22.uP9tLpAQ3,Ketoconazole; tretinoin,2,2,0
e3bs9.2V9TAjYjlclD7nHA4G25TITRwQ.oEH0iM0eJ0Y3,carboplatin; propranolol; vincristine,3,47,221
e3hHoq8K-ndnx.BvQ5UoOkSL5rg7.5IV012ZPN3GbUuI3,Cyclophosphamid; Cyclophosphamide; cisplatin; filgrastim; pegfilgrastim; vincristine,6,82,217
e3hXoBCVS8e1lfPEUZuEAuUdWlM6g-UHfY374AJeWfmo3,ATRA; triamcinolone,2,8,2783
e3s7AegGCcFYVKrDabP2KlBfl7ryFqGErK0xVRFzlnXo3,Cyclophosphamid; Cyclophosphamide; Fulphila; azacitidine; carboplatin; etoposide; filgrastim; pegfilgrastim,8,123,3243
e3thFaxpXMYx4KcPBiJIkASg6yRMMpJtT9uWjfOgkz043,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pembrolizumab; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",112,384,248
e3y0J2sxQt4bLVrucvqQLEA3,Chemotherapy; tretinoin,2,2,0
e3zgto6rPS4z6hlC5e3f.yer34qdyhn2IP-BwngawhT03,Ketoconazole; Keytruda; Stivarga; Temozolomide capsule; Ziextenzo; bevacizumab; cisplatin; dexrazoxane; doxorubicin; lomustine; pembrolizumab; regorafenib; sirolimus; sorafenib; temozolomide; triamcinolone,16,111,533
e45a0iecErvywGUU-G0VfK2uXaAQuI1j.ovkC6NNLKx43,carboplatin; vincristine,2,130,461
e4BwD8ZYDBccepXcJ.Ilo3w3,Ketoconazole; Koselugo; Vinblastin; bevacizumab; selumetinib; tretinoin; triamcinolone; vinblastine,8,182,1866
e4DfkXefqPKQ1yBPF0xtLJw3,triamcinolone,1,1,0
e4ENrlVxP2W5fA4oEVaYtYNUs4iuUruR7eYpz8ZRb63g3,Cyclophosphamid; Cyclophosphamide; Valproic Acid; bevacizumab; cisplatin; etoposide; filgrastim; pegfilgrastim; vincristine,9,86,406
e4HzEtf5nPT3weCHFYM0dE14VKGTUlt.f-YmgOG8UyZw3,bevacizumab,1,24,160
e4XgcYAZEn99QzCQ4acHvctCiz62OYdJ2ry7Z8uCaOU83,Ketoconazole; Koselugo; Vinblastin; Vincristine Sulfate; bevacizumab; carboplatin; selumetinib; triamcinolone; vinblastine; vincristine,10,563,4451
e4aSm7E4S6gSgeONTvIB.MODbZP.ZJGa4x6PkQFLOjNc3,temozolomide,1,3,0
e4nBYf8nvtbec44KaGGEqmoT9L8WjcQ-iAwrfZSGOXtg3,Cyclophosphamid; Cyclophosphamide; Neulasta; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; vincristine,13,281,363
e4vIskMdg8LpC8rLx2WbmMBzBcQSDumMeZw3fIH3pEns3,Acetic Acid; Vinblastin; clofarabine; vinblastine,4,57,3685
e4vbBCq1KughH7m8AL5QQMYucyV9XSXozlWkOlmyuWoI3,Cyclophosphamid; Cyclophosphamide; Neulasta; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; rasburicase; vincristine,10,32,193
e4vk6-YqqlCW7z-OtORKzmmnLKZhWq4WO4AzKLxWnzq03,Testosterone Cypionate; lanreotide acetate,2,20,916
e51Ib8Mk6DfHJSKG.9QGFs.1PQSwE-Ku8NTbpKl1ujZc3,triamcinolone,1,1,0
e56MklrwGIf2a-C243FEPXUglkJEcL7pTTD1WQi.REG03,Afinitor; Valproic Acid; everolimus; triamcinolone,4,71,2743
e5911thHVYNfSNoS2jXnGARRFWA-FHupC-DKE1Jc9xN83,Acetic Acid; Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Ketoconazole; Leucovorin; Sufentanil; Valproic Acid; amifostine; cisplatin; dexrazoxane; doxorubicin; filgrastim; imiquimod; mesna; methotrexate; pegfilgrastim; ritonavir; triamcinolone; vincristine,21,206,2907
e59YoMuN3bFvWTWcZmQOgkbjYSyL7EOxpJiJ-GEOc0dg3,Valproic Acid; bevacizumab; lomustine; temozolomide,4,19,161
e5ASwrp4u4SatykBN13x8tO96gYwjojvPdg2HrwKPDZw3,Afinitor; everolimus; triamcinolone,3,35,1872
e5E6PP.JUAelStNjdT2jrbQ51p1Gc5uu2VFMMuPiXPko3,Acetic Acid; Investigational Chemotherapy (unspecified); Ketoconazole; Leucovorin; Progesterone; Stivarga; cisplatin; dexrazoxane; doxorubicin; filgrastim; methotrexate; pegfilgrastim; triamcinolone,13,116,856
e5EGcCLs.6r6G51rF1qaitQ3,tretinoin,1,4,146
e5IdajrfQ17-khXDaj97.bQJlzhwuPP.UaM2zu2-c9E43,Cyclophosphamid; Cyclophosphamide; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,12,140,466
e5KmpHORua.4NkhBIuJYanf5wRG.4pikYkHr7YuplMlA3,ATRA; propranolol; triamcinolone,3,3,255
e5LM3CPQRqE51Fdp0-dPYmma8.Dxy9w8JXzs2UvNf.NM3,Cyclophosphamid; Cyclophosphamide; G-CSF; Temozolomide capsule; Valproic Acid; cisplatin; etoposide; filgrastim; irinotecan; mesna; pegfilgrastim; plerixafor; temozolomide; vincristine,14,158,260
e5SMMS4-C1vsdq4lEJ-SDQb89P6zl9ZgMaSLnZsfoDOo3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Ziextenzo; carboplatin; cisplatin; etoposide; filgrastim; ifosfamide; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,18,171,595
e5WOghnmiqZMAYvDV7vg4F0QokAgX9MpK2mSiTD4vYyw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dactinomycin; dasatinib; dexrazoxane; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",121,568,221
e5di6EogPi6f5uEX7X4-a94OCrTHftYkP7ul263QY95k3,Bleomycin; Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; Glutamine; Granix; carboplatin; cisplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; etoposide phosphate; filgrastim; irinotecan; palbociclib; pegfilgrastim; plerixafor; temozolomide; thiotepa; topotecan; triamcinolone; vincristine,24,218,1208
e5i9tfZmfGuLveEPTy6L0wtES1ifNXMyOtMhORZfF6TE3,Temozolomide capsule; Valproic Acid; bevacizumab; etoposide; irinotecan; temozolomide,6,83,238
e5wdTmiSn43MOxBfJWw4aNu503nY1mT3CfR3y5LWQZz83,Mekinist; bevacizumab; carboplatin; trametinib; vincristine,5,137,1409
e5zwIU2eWQrApyFANqqezDFIjxTHlqECFxCmyCJAMnZM3,Cyclophosphamid; Cyclophosphamide; Valproic Acid; bevacizumab; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; irinotecan; methotrexate; pegfilgrastim; temozolomide; topotecan; vincristine,17,265,509
e6E39F2dgnXukO6icCEVFwediRe4ah0djf0i.Reua4803,Temozolomide capsule; Valproic Acid; bevacizumab; irinotecan; lomustine; temozolomide,6,234,1355
e6HCmzN9HuXvtx0Fa.XsXoOxPcOigu5Qfn5mhSEwDt5o3,Cyclophosphamid; Cyclophosphamide; Daunorubicin; GM-CSF; IMPACT; Leucovorin; Neulasta; Progesterone; azacitidine; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; gemtuzumab ozogamicin; ifosfamide; mercaptopurine; mesna; methotrexate; pegaspargase; pegfilgrastim; triamcinolone; vincristine,23,381,743
e6NyRVld8oc7dA5gkerAHfg3,Tabloid; Testosterone Cypionate; Valproic Acid; lomustine; procarbazine; thioguanine; triamcinolone; vincristine,8,81,4000
e6RLjWbMLRX4bj5PzeQR9O9PpmjH9E2D6j2At5SMHGmI3,Cyclophosphamid; Cyclophosphamide; G-CSF; Zarxio; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,10,78,104
e6clCgHRIjK3PYdyE9ifTDcPURe4yPIQa2p7nxrXmbkI3,Cyclophosphamid; Cyclophosphamide; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; vincristine,9,118,194
e6t7uDepX1loFn5cg04thi8ByRovFkXFJdJVYvpYZq.83,Zofran,1,1,0
e6u5eIM8SedggJgz8VvBwBw3,Ketoconazole; carboplatin; sirolimus; vincristine,4,120,1177
e6wiwijWIviHdLCszW19qgFlR0PgrrA5URMzKpeyggHs3,Cyclophosphamid; Cyclophosphamide; Daunorubicin; Emend; G-CSF; IMPACT; Mitoxantrone; Nivestym; Rylaze; asparaginase; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; gemtuzumab ozogamicin; ifosfamide; mesna; methotrexate; pegfilgrastim; plerixafor; propranolol; romiplostim; topotecan; vincristine,25,370,1567
e6wqMejPFaFRAuBriKXneqbRuHeOB5DtYF4Blwg67t.03,Calcipotriene; Cyclophosphamid; Cyclophosphamide; G-CSF; Ketoconazole; Nivestym; Ziextenzo; carboplatin; cisplatin; filgrastim; pegfilgrastim; triamcinolone; vincristine,13,103,257
e6yq.kqFmT2pty9E4Cdq.3Q3,ATRA; Valproic Acid; triamcinolone,3,20,3449
e70y9MPPyCRt46756G5J7ZnzjCcNe7xp3CvV4DKZEOlM3,Temozolomide capsule; lomustine; temozolomide,3,6,0
e71yXwjcS3sKYNkMH9S0xN.SIslY6Ureemh08ZIRuTBU3,Cyclophosphamid; Cyclophosphamide; Etopophos; Fulphila; G-CSF; GM-CSF; Glutamine; Nivestym; carboplatin; cisplatin; etoposide; etoposide phosphate; filgrastim; mesna; pegfilgrastim; thiotepa; topotecan; vincristine,18,144,279
e73Y.OmWnFdFoCEQ5emhEcQ3,dotatate; zoledronic acid,2,8,1287
e74qyk33cyIrBd.Wzz-7WPjLWswZFm.rz2JBRGJN2Dnk3,ATRA; Cyclophosphamid; Cyclophosphamide; Ziextenzo; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,12,102,101
e78x72htBOAlMbKAlhp08IwtqQMjtsWXEEgrt0ysiyBI3,Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; Glutamine; Nivestym; carboplatin; cisplatin; etoposide; etoposide phosphate; filgrastim; mesna; pegfilgrastim; plerixafor; thiotepa; topotecan; vincristine,17,144,174
e7APWcUaHic4VtkXSiJZeWb67lac-XpY3JhyT8i4KT303,Testosterone Cypionate,1,18,2360
e7ElZ9omvhYn8PqT-VLVC6jt1HJ63JMMTTqanNCcV6II3,Temozolomide capsule; irinotecan; temozolomide,3,8,0
e7Gd-BP1LKtvy.pieN32ycKIm-CPZY41ArfMyCBQbzcI3,propranolol,1,1,0
e7IoYL8Cv1GiLZy9DbbTiK-BomF2HF-nqFJdNbLISbVQ3,ATRA; Cyclophosphamid; Cyclophosphamide; Neulasta; cisplatin; filgrastim; pegfilgrastim; vincristine,8,67,190
e7KTovogaeFYoLBQ6rjg1j0M9bPgOFkDSZhbzFlQhybs3,triamcinolone,1,1,0
e7LVbKOLGM7fMkhvJYK01TkEHMWxgVv4ezb.f4N5TW-83,Cyclophosphamid; Cyclophosphamide; IMPACT; Neulasta; acetylcysteine; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,13,185,3867
e7NRlYK4UD1SuQ9.DEShT80i8MJOJDuilkpNnJm3VfhQ3,Lupron Depot,1,1,0
e7QeQa-7YYe9kZ9Pj2Z-fLdmeJdzbhOTP-8agT62pAo03,cabergoline; lanreotide acetate,2,42,1352
e7bDp12viVsfqEVAhPn7HhBdk.FZzijr05pzz.rLcjY43,Hizentra; Sildenafil,2,11,2855
e7ciWZAxqsV6jzt0uOOKKB12lv-GviOzp9Gf2p8XD44U3,triamcinolone,1,2,28
e7e5oMNysWKQHCYmSxqqY1hFgYoYqsZDrS3yfatZY3pU3,Tabloid; lomustine; procarbazine; thioguanine; vincristine,5,59,383
e7eUuihzR-QXNWXWAL4ZZkmbb4G-lsl3E-agtWjmLsvA3,Oxytocin; triamcinolone,2,7,2355
e7eZKNV0aXpjv334nPuVSwHDsqccDHTYX0bAO8AazfBc3,isotretinoin; lomustine; procarbazine; thioguanine; tretinoin; vincristine,6,48,368
e7eh.4RQtMTEYDqsskp2S7KnC7kuANZHJ.9pOzUEZ5ig3,Cyclophosphamid; Cyclophosphamide; mesna,3,35,180
e7f2UZbydpbgSNO4zqM8pbw3,acetylcysteine; tretinoin,2,2,734
e7i-aSpdFYktoE93FIOTV0eJbQNndvRH2Q.STL4PhpCg3,triamcinolone,1,1,0
e7im3IMp90Gh28Fvwk4WV9kpvQ9ckBV4vMM.YoMF85G03,Ketoconazole; Lupron Depot; Triptorelin Pamoate; bevacizumab; leuprolide; leuprolide acetate; triptorelin,7,25,2296
e7sgq6l.Y5smDZ.bAJCdKrskOfJFpOB4tVrxiRA6FcyM3,vincristine,1,12,34
e7ub34.Cr3WdyZNzAIa8AjPWZJAntNGTQH1rhX8MRDWQ3,triamcinolone,1,3,24
e7wx9ChzUQHvJP3z9WumjT5fKt4ZgEgDZxbW66If0ids3,Vincristine Sulfate; Zofran; carboplatin; vincristine,4,26,62
e7xnb-dI5hDnX0wsybWLrTw3,Progesterone,1,1,0
e807NrLuxQQqOu4ZlWrq5YgiTib7Qfm3RjqH2j2A4KjQ3,G-CSF; Glutamine; Neulasta; Progesterone; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; plerixafor; thiotepa,12,101,629
e8AGV-pcZry61qNpyfzUV1g3,tretinoin,1,3,1043
e8ErdxYCE8yIs6ch9nfKxG3wx4JqbLy3QvUKw0XLsE4Q3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Emend; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fenretinide;;Dose; Fimepinostat; G-CSF; GM-CSF; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Octreotide; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temodar; Temozolomide capsule; Testosterone Cypionate; Testosterone Gel; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; dexrazoxane; dinutuximab; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; plerixafor; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; topotecan; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",136,5378,3918
e8JizE8TKgFf0-eYtCDUBMQa7eOhwVDaH.kB-Y4uVv543,Temozolomide capsule; temozolomide; trametinib; triamcinolone; zoledronic acid,5,28,1784
e8Knml9k338EbpluOjb8zs0svSsnoDkuf.YHVTkpSLk43,tretinoin,1,1,0
e8SOWZ74xDHVgLwF1g29fZvCkz5vaQNq-Fkv0hHZAdms3,Cyclophosphamid; Cyclophosphamide; carboplatin; etoposide; filgrastim; pegfilgrastim; vincristine,7,80,161
e8XUZfL9-sgUQ.zzbFSKP4mLw891dPo2zOFvUlc1TcQc3,carboplatin; vincristine,2,146,399
e8iLiu0auylYO1EQYfZptvH.0BkOHdmEg6EfXBZKkjFE3,tretinoin,1,1,0
e8jPD8zawpt.KIpA97WuwdDCHyK.qEO5mX-6tEB7krPU3,IMPACT; Temozolomide capsule; Valproic Acid; lomustine; temozolomide,5,25,241
e8jvrF5IozRmfwySdwoRVwz02sJVXqC2b0q7DVAmDDcQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Leucovorin; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Neulasta; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; dexrazoxane; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; filgrastim; gemcitabine; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; methotrexate; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",121,565,927
e93dd0ZEMUWVhxzOXiQ687g3,Apatinib; Avastin; Investigational Chemotherapy (unspecified); Valproic Acid; bevacizumab; lapatinib; lapatinib ditosylate,7,178,3260
e98plOP9ofeIligJe.GYyFWheGEP6ecrl6BxF.kOHFVw3,Cyclophosphamid; Cyclophosphamide; Valproic Acid; Ziextenzo; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,12,191,244
e9928Ob8xk5xOoc-dCvSKUUB4uu0qun3mruwy-KFg89Q3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib,5,30,575
e9FdCgOz0OTUdZr-meYD8o5bj6HtpzmGmKRXKTrlDh.A3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib,5,26,172
e9LrbcJWxR3GbSCKqIF1eMA3,Progesterone; bevacizumab; etoposide,3,79,558
e9SBdLJEspT1USy.g5Rhl1A3,Zofran,1,1,0
e9Tg5MT7es6WlVsSqDjB5uQ3,Progesterone; Retacrit; epoetin alfa,3,23,876
e9eLr4-tjRkbRtd6ojMC9ZBePS-cUBTORH2jC5tpFWOM3,Progesterone; cabergoline,2,18,2172
e9oRlT3VwO.3Wi4q2rm6soI6qhKaV6di6yv.E4KPF61o3,Avastin; G-CSF; Glutamine; bevacizumab; carboplatin; filgrastim; temozolomide; thiotepa; triamcinolone,9,20,631
e9xlNeYeDBlDnYrqArSYbs8ExtA-YAH5HhryO1u1xWOs3,methylnaltrexone,1,1,0
eA0wzx8Ta6OdZ5J6UU8wudjsYEH0nvVSTzkOGU3Nj4Qc3,Valproic Acid; tretinoin; triamcinolone,3,4,407
eA22AFCqrWbkIB4kz1fzl7KNNm740SiyIgeu8j3EOMs83,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Investigational Chemotherapy (unspecified); Nivestym; Temozolomide capsule; Valproic Acid; belinostat; bevacizumab; carboplatin; cisplatin; entrectinib; etoposide; filgrastim; irinotecan; ixazomib; mesna; pegfilgrastim; plerixafor; temozolomide; thiotepa; vincristine,24,250,987
eA2yieGcoG6aOIOCXLfXvntMKLG7JPVU21HCOMpWwEeY3,bevacizumab; triamcinolone,2,5,137
eA7YSWIz3IQa.dqVxwJ4JK9fFLDt4MkxdpjzugEPdWrQ3,triamcinolone,1,1,0
eA7z9azeNDHeVaWHRE1dAGg3,Lupron Depot; Valproic Acid; Vinblastin; Vinblastine Sulfate; leuprolide; lomustine; procarbazine; thioguanine; vinblastine; vincristine,10,128,4074
eA9lAYCUFXoCaihUZnbojQxew9tA3nAxoCIJhggKBuDs3,carboplatin; vincristine,2,12,116
eABp.WZm630g7426eMq-w5fdVvbCI54rAUIWzTvZ29Gw3,Valproic Acid; triamcinolone,2,7,1200
eAIcYT7LLSbgsmcQ2u0H7337rpPeEdplGnw6W9l3eVfU3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Valproic Acid; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; temozolomide; vincristine,12,124,359
eAl4tMpAG5TdHh1wDuHDydI2dzw24H6HoZ62PSLz4BLE3,Cyclophosphamid; Cyclophosphamide; Neulasta; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,11,183,198
eAnrjHyFylxirVYLw43PGhY4t-Du3UCVP.RQAU5NtxW43,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Infliximab; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vinblastine; vorinostat",114,214,1946
eAnx7R2Zlo0exvFaZuPAs6eWLC5QjHp8ICAfEeNj4Gq03,ATRA,1,1,0
eAoSD8LBYdL7buMj36zu5tTmdDP9TW0iEe6hbxMsiLRg3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Valproic Acid; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,15,340,566
eAs7bZORs6Ntmk7ZJfY-Bw8odbleQzaeHOQRXYzYrIoI3,bevacizumab,1,12,69
eB-hPIF-blxOZ8qS6QKwXIhyaPcAvMezONJnNAq.oNUo3,Dabrafenib Mesylate; Mekinist; dabrafenib,3,6,1
eB.JfkGUgTii0ROWcqpWnnIqO37SHnulBoDnshgq3R-M3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; acetylcysteine; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; triamcinolone; vincristine,13,59,121
eB.deQelZvW4OvA.kDKwg-GwveuaDX3Mqu7yPVDkMWs43,Cyclophosphamid; Cyclophosphamide; Etopophos; Fludara; Fulphila; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; dasatinib; dexrazoxane; dinutuximab; doxorubicin; etoposide; etoposide phosphate; filgrastim; fludarabine; irinotecan; melphalan; mesna; pegfilgrastim; sirolimus; temozolomide; thiotepa; topotecan; vincristine,27,278,782
eBFsx72H46uwsR7U4OVQgh9H6tCOtC5IqDF2NX8RATIg3,Cyclophosphamid; Cyclophosphamide; Fulphila; carboplatin; dactinomycin; etoposide; filgrastim; irinotecan; mesna; pegfilgrastim; vincristine,11,246,612
eBKEJApEF3tI88euZ7H.OYfxPXaPzM3eg2ybv1lcUVxY3,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,10,191,204
eBL-5UdQmTdtnV74vkQXYlfi4dlz5c6QY1p6hFaFTs9w3,triamcinolone,1,1,0
eBOzgzJgjuTRfdFvlPuaqeA3,Progesterone; bevacizumab,2,132,3205
eBPsEpSXcOQbWdpnYddELi-Sg2ZAuwH0X-zRK9B00ZaI3,cabergoline,1,1,0
eBQPzzoTGBRL19BT0QwuQfw.P66TvSpXtMygZa4xSeus3,Afinitor; Tagrisso; Verzenio; abemaciclib; everolimus; lomustine; osimertinib; osimertinib mesylate; triamcinolone,9,41,234
eBdAoOvpCbR2kqtVIwHKEFngVqeJ-VZ5gXSrPcFHExlY3,carboplatin; vincristine,2,146,416
eBlU-..hIK.nSyj7u6hyWzJIClnf7ZFSGxDB7gob6S4c3,Temodar; Temozolomide capsule; bevacizumab; irinotecan; pembrolizumab; temozolomide,6,140,2520
eBlxMAv3WwHL5fX-2XSqU3Bkh-YgRXBu1jpdRxkSxCX03,G-CSF; GM-CSF; Glutamine; Testosterone Cypionate; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; plerixafor; thiotepa; tretinoin; triamcinolone,14,172,3257
eBn2wdEhOPGVFxrhnS.Y.PZygnm77gT6uEpyjQlsdGUk3,G-CSF; Glutamine; Temozolomide capsule; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; plerixafor; temozolomide; thiotepa; vismodegib,13,97,1408
eBu1NBakdyPob7C2NTdZsRskZGcNQS-iul8iO1TyM-xU3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Valproic Acid; amifostine; cisplatin; filgrastim; lomustine; mesna; pegfilgrastim; triamcinolone; vincristine,13,104,1868
eC.nXxYPj4zsc1jo51UblyuNRsR3zeWeo-5wX6gltPy03,Ketoconazole; Koselugo; bevacizumab; selumetinib; triamcinolone,5,31,721
eC2fTZ63kea503cCHjyLoQvOGmJgaOFltrUxZzjsb87M3,triamcinolone,1,1,0
eC73JHiWz7FCXrqBqHo9CaE.L5Sv8DXzRWA4qgM2Xbhs3,IMPACT; triamcinolone,2,3,1605
eCOY2JcuFHh0qEUKWjviRJTq525nMJwTyTb84D8y-S4c3,Cyclophosphamid; Cyclophosphamide; G-CSF; carboplatin; dexrazoxane; dotatate; doxorubicin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; temozolomide; triamcinolone; vincristine,15,138,379
eCQ6zysbssLZaJEhGv9I9zk6K4cD-9xnS.MadeppKCnU3,Placebo,1,1,0
eCROTjFR6PQZFnuXwGvSNylEwx3PKeEupq3AkOrr.fyw3,Arimidex; anastrozole,2,2,0
eCSYXylrIK.ovszBk33YiDXywXdgqwfyMLccIgUvY0h83,Cyclophosphamid; Cyclophosphamide; G-CSF; Pentoxifylline; Valproic Acid; Zofran; cytarabine; dactinomycin; dexrazoxane; doxorubicin; filgrastim; methotrexate; vincristine,13,157,3723
eCW.3VvEg18tvx9SMDzPtIXcVl2pvcBqSxoGGjviv4oY3,Ketoconazole; temozolomide; triamcinolone,3,3,10
eCZ1beZXa5YoZT4wUo6xAZWbCa7n-MMeoPALR0NCcimw3,triamcinolone,1,1,0
eCbaoLbbSuKaVCDvAdXswCw3,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,10,199,204
eCfMGFo6sM6iCdBMl82gEUqjpAzxs.hihZHwHs0Hfhqs3,Ketoconazole; Lupron Depot; Progesterone; leuprolide,4,9,1284
eCfh8v1vamiIt9G3D.ak1iQ3,Lupron Depot; leuprolide,2,8,254
eCgVGwFmEXUUBrPlhHWdXx28LpPGDJ8gtPPLEvi8FUMs3,Cyclophosphamid; Cyclophosphamide; Mesnex; Zofran; etoposide; temozolomide; tretinoin,7,10,589
eCiVlpTET9y5W8rb3tkgF2AEpARknJTmCxGwGSZjYD2Q3,triamcinolone,1,7,980
eCiYL9pwKLsYSIgWTcmBmZ5pq57EPy.DeQptSPUXmWiI3,Temozolomide capsule; bevacizumab; carboplatin; lomustine; temozolomide; vincristine,6,121,1101
eCt82-1HdMDFKzvV6B91jLqnDUtPKgtjw5p3TtvMZGi43,Octreotide; Somatuline Depot; cabergoline; lanreotide acetate; triamcinolone,5,25,2543
eCvFWzYkAziXQOtcPwqjSuQti-TBN823s0wFJUQsmFaw3,carboplatin; vincristine,2,144,454
eCw0mrjWDGG9N548VPTU-asLd78NSUnzGMWasEz7xvtQ3,Progesterone; Valproic Acid,2,14,2672
eCxHfLCI.b3ZQzhNUZ9.6NcGBIc.FfCLGS0-lg2rispU3,G-CSF; carboplatin; cisplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; plerixafor,9,85,132
eCzYB.gyvCsTiTjNFLHA.2XS6CYDDJwtdZdDg67lEtZA3,dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,54,72
eD-4fwMswEMxKkyDZQaoGVSjAwaFAEpUx2.dw39nsHwQ3,ATRA,1,1,0
eD-mFdgB8Be-UqGTxbAZ3cw3,Progesterone,1,2,400
eD0nvc64-lP2LxNayVJzoyU.RCs1Pt7pf3L9v.bj-e043,etoposide,1,4,49
eD4V7sxVywXkOOGbxjdDajhMdt-9ayFiW211KbcfVDt03,ATRA,1,1,0
eD4vRno8nNlJq1QiylGVw6s4INg-yqdbfacFjK5mbhew3,Testosterone Cypionate,1,13,2417
eD61uDJM0hiNiVPQj5e6rt8oUM9PJcrhBkz9Bq3RuI.U3,Progesterone; Ziextenzo; carboplatin; etoposide; filgrastim; pegfilgrastim,6,26,665
eDCN.RGMWQgUqVu4-7l71eV9DGmBbCL-6LXrLhedTog83,filgrastim; pegfilgrastim,2,8,1
eDGWpnXCih0aquOCPvJOik7IFsFMVKJoDOLyFHGBKglM3,G-CSF; filgrastim,2,4,1
eDILMhfSLjBSya5cMca1U4xoUHYoUdaQJSAOoY78UwFs3,ATRA,1,1,0
eDLhlaV2e0v92XJrLQw5CY0hKtEiEdfnMoawKGg-cX803,Tagrisso; Temozolomide capsule; bevacizumab; etoposide; lomustine; temozolomide,6,33,260
eDMSE76TIjFihAanEpG-Glc76Q-uWuiAX3THEzfO3PIk3,Testosterone Cypionate; triamcinolone,2,10,4840
eDVMO2hz0QmYdCW-Dc7BGnup4LzdLsGpvU8uJAoJ3nLA3,Actemra; Adalimumab; leflunomide; methotrexate; methotrexate sodium,5,7,2802
eDZZrBz8ZCHic56TVxu48S5XR3D3Di-hrkcZrL7gZzUc3,Temozolomide capsule; temozolomide,2,2,0
eDe5UjX7En3Iixny2a4NfFUgmjOLT8R7CqPoZvnczsss3,IMPACT; vincristine,2,13,35
eDe7IanglsmBppe3htvO-QdYT26-v54aUqFAeTPQSJ6w3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,550,112
eDeuCbH6cM5zDQCyObrrON6TpcZIIP.uiU6t-zYUI.mU3,lanreotide acetate,1,2,0
eDgr-DlXzAtCbaNggIsI3pfudLvMhJKZ7RNd4n2lYJB43,Cyclophosphamid; Cyclophosphamide; G-CSF; cisplatin; etoposide; filgrastim; mesna; vincristine,8,24,79
eDhMnToYd0f3t0pRWOLC8yQ3,methylnaltrexone,1,3,6
eDkG.RFtxAUP.8iAlEnPoPN8yI1F3opkgLE1WnJpBskU3,Cyclophosphamid; Cyclophosphamide; Ketoconazole; Temozolomide capsule; carboplatin; cisplatin; etoposide; filgrastim; lomustine; mesna; pegfilgrastim; temozolomide; vincristine,13,454,973
eDn-4kW4P-bETt4alqu9nHa4tzzobECFkQw3TvDOnzPo3,ATRA; Mekinist; Temozolomide capsule; Valproic Acid; Zofran; carboplatin; lomustine; temozolomide; trametinib; vincristine,10,209,3771
eE-9ivni6NAsgMHLxYQLCOippPQChCbLec3mBfxTT0EA3,Cyclophosphamid; Cyclophosphamide; cisplatin; lomustine; vincristine,5,96,376
eE.rkTumb8UZlR1VMTA9yeg.XliPJP6INuRRsSOhFgRM3,bevacizumab; carboplatin; filgrastim; pegfilgrastim; vincristine,5,242,2307
eE1I.lrN5-990SmHgBJNG4hWW6FuV86E3PCz4hpCf4343,Chloroquine; Cyclophosphamid; Cyclophosphamide; Cytoxan; Hydroxychloroquine; Rituxan; mesna; rituximab,8,52,788
eE3hHHv77IevUkv43i8JlCNgePorTN622WK2rR04oHmI3,Cyclophosphamid; Cyclophosphamide; Emend; G-CSF; GM-CSF; Glutamine; Progesterone; Temozolomide capsule; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; ifosfamide; irinotecan; mesna; pegfilgrastim; plerixafor; temozolomide; thiotepa; triamcinolone; vincristine,22,336,2069
eEGDsvB.tMVEync.LgaKKNBP2uJXR.Sp1OvVKDOIFTOk3,Cyclophosphamid; Cyclophosphamide; cisplatin; lomustine; vincristine,5,99,395
eEHXqKWgp-Y0MrWj-iD1eBvbqfvybje13pwH9xGaguxQ3,ATRA; G-CSF; Investigational Chemotherapy (unspecified); Temozolomide capsule; etoposide; filgrastim; ifosfamide; imatinib; mesna; pegfilgrastim; propranolol; temozolomide; triamcinolone,13,207,470
eEJcrpDHtP-6cfR7bRFzo4rcdRi2fSkhGm.GuVGnCOSo3,Cyclophosphamid; Cyclophosphamide; Ketoconazole; Vinblastin; cisplatin; filgrastim; lomustine; methotrexate; pegfilgrastim; vinblastine; vincristine,11,424,2988
eEKHVUJyzVSC78Xc20.NmN29pspvvvaYufyus5iGtUx03,Vinblastin; Vincristine Sulfate; bevacizumab; carboplatin; vinblastine; vincristine,6,339,882
eELFj7oZ047Xa7oE1jSG.LrMFgtPZP7864UyuiWTFy383,G-CSF; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,75,141
eENsZfsiMUEzMun873Jrq-AoQHwspzn3dTsJsGmLGHvs3,Ketoconazole; Mekinist; carboplatin; trametinib; triamcinolone; vincristine,6,170,1340
eESojeYjHTp7U0.DgACDrCpGkcV4Zd5pYdUbAh3LkJcs3,IMPACT; Valproic Acid; bevacizumab; triamcinolone,4,20,554
eEWGnSHhcbTFu69w9FtOIHg3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; isotretinoin; trametinib; tretinoin; triamcinolone,8,29,454
eEbHX6hcC0EMsM5CX8dfmcY.jHrSkYRutQPCn8M9TdxM3,ATRA; carboplatin; dasatinib; everolimus; triamcinolone; vincristine,6,62,667
eEbZuKwlymbVrWXlYjhi1-uPh8lO3VtUTLgBHqimgMsE3,Dabrafenib Mesylate; Lupron Depot; Mekinist; Tabloid; Tafinlar; Testosterone Cypionate; Valproic Acid; Vincristine Sulfate; Zofran; bevacizumab; carboplatin; dabrafenib; irinotecan; leuprolide; leuprolide acetate; lomustine; procarbazine; thioguanine; trametinib; triamcinolone; vincristine,21,406,5016
eEbn6q3JnVfSN5mjOpqQObxWedVsvQSUW.sCrF-fuaNA3,triamcinolone,1,2,51
eEdNLGCLV8d5yGOO95cm53w3,Progesterone,1,1,0
eEf4vwgS4hL1C43UGQ-WgMA3,propranolol,1,3,37
eEfM1WcdQ1u4au2MK7i5rV5eVbzbnI0YEa8XjsA4x4Zs3,bevacizumab,1,6,26
eEhOHfbvyBmVrrdag.9Tkzg3,Cyclophosphamid; Cyclophosphamide; Lupron Depot; Zofran; cisplatin; etoposide; filgrastim; leuprolide; lomustine; pegfilgrastim; vincristine,11,65,1321
eEhidH3b22zDf7Q0ZEOQGLw3,tretinoin,1,1,0
eEjVAov.ZXkB8SEtGC4gmSn20X-5jjC1sZbMSn9.OSWc3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,14,294,673
eEmkzrzlaOPrI4Z379yELSQ3,Arimidex; Fludrocortisone acetate; Lupron Depot; Progesterone; sirolimus,5,6,3068
eEv9FDhOXJovCR53.vVvK7Q3,Temozolomide capsule; bevacizumab; irinotecan; sirolimus; temozolomide; vorinostat,6,187,615
eEvtdg6h5gSzQG4uCMYLK4n9nCbSGqEMeDFEkh4E5T3Q3,Lupron Depot; leuprolide,2,7,25
eEwwhNdTr1arwj2JYYAS8.CNqZi6tB6p70CT-b6VmD9U3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",116,1721,2222
eFIVts4YROq4o9aaHDhV9fw3,Temozolomide capsule; Valproic Acid; etoposide; temozolomide,4,28,134
eFSfyaE1MJUtbW9bpVAsgVg3,IMPACT; Placebo; Temozolomide capsule; Valproic Acid; Zofran; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; irinotecan; mesna; pegfilgrastim; temozolomide; vincristine,15,204,1001
eFTX8hcnZRd1B12YCHbICcOYQgCpnZKcAWcU7MUdMM783,Acetic Acid; Cyclophosphamid; Cyclophosphamide; cisplatin; etoposide; everolimus; filgrastim; gemcitabine; isotretinoin; mesna; pegfilgrastim; pemetrexed; tretinoin; triamcinolone; vincristine,15,135,2109
eFW8vDIBGOR0z4EUeVrR9nhwYzjKKhjOjetZOMdfKZBU3,Temozolomide capsule; bevacizumab; temozolomide,3,55,281
eFYCZg6PFC8fmMrrEJ7daTIKWbYhtzH.9Ab4azIJJMy43,Gonadotropin; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,56,2502
eFdBYoBE7n0HDmjF-VpPTOkUaMDOJCUeUrjDXCxpoJH83,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Leucovorin; Neupogen; carboplatin; cisplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,19,254,325
eFfOVk2Ufw2E8Pblxnwcyaw3,Vincristine Sulfate; carboplatin; leuprolide; vincristine,4,252,1841
eFhNJqD0bDeN1Ctwm1V7fxw3,Investigational Chemotherapy (unspecified); Testosterone Cypionate; Testosterone Gel; larotrectinib,4,35,2476
eFhg.k-Ol1TrG2k.bQTXWUYX6brNY0cZzt5HIi442ouc3,Testosterone Cypionate,1,23,1244
eFjBlEXSE9PaUIZSB7jQdOTzJabqpcKmx7sQzWHju4yI3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lenalidomide; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thioguanine; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",120,2907,4206
eFkHu0Dr07HPadEPDpvudcQOsKqv2vvCvdg-a-r-8SVY3,Valproic Acid,1,4,1
eFnA0n-SHzwmrELws9VcafIC66ozeTs3Fok2PMDtJnu83,Testosterone Cypionate,1,3,245
eFsOPc5iTfEU4QQLnhw8PlgD7Zgk5SGGQsYKoDcBHcCo3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Ojemda; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",116,1175,1128
eFwl-xKGLZmxlQnoqhYT8pGvR6S34QDwtrKDLGAOoe7E3,Cyclophosphamid; Cyclophosphamide; Investigational Chemotherapy (unspecified); Neulasta; Temozolomide capsule; Valproic Acid; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; irinotecan; methotrexate; pegfilgrastim; temozolomide; thalidomide; vincristine,19,203,504
eFxnTOHVPicH5w5Y5QZ8X9ofnw92U1uO9YxDXcOX0zZk3,ATRA,1,1,0
eG-4tqnNPX74p.1j5tJC8oA3,tretinoin,1,5,1421
eG.zmhyWrMOHhH.FkBlfL5A3,Ketoconazole; propranolol,2,11,2574
eG4ShTUqW2qNwGPGJ3ogMIhSLTqrk3WU6gfjcRNquvEI3,ATRA; Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Leucovorin; Zarxio; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,17,120,123
eG9QCINy57bcJ89rsXYmLhxN.xhHsEeowDMCcUA65Xyo3,Bleomycin; Progesterone; carboplatin; cisplatin; etoposide; filgrastim; pegfilgrastim,7,62,1314
eG9zotKPotIYRLU-eZXBpTbhaztFXVBKmoWdRY9sSuh03,carboplatin; selumetinib; triamcinolone; vincristine,4,147,1280
eGEObogyjWCTASWgife7oEn-ha9B9W5iXnLWwNQKnRT43,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Octreotide; cisplatin; dexrazoxane; dinutuximab; doxorubicin; etoposide; filgrastim; irinotecan; mesna; pegfilgrastim; temozolomide; topotecan; triamcinolone; vincristine,18,216,771
eGFJqPu07NCmQaO4okGvCbw3,vemurafenib,1,8,218
eGHWA3yk.4.WcWwUgMnfaYkKg2OZEgsktx43U3WBkEck3,Dabrafenib Mesylate; Mekinist; Progesterone; Tafinlar; carboplatin; dabrafenib; trametinib; vincristine,8,202,2303
eGKTtVECSsHjgIj9rZuq2srjQsT.N-Ak1L8YarJq5E5E3,Ketoconazole; Progesterone; Zofran,3,14,1055
eGOvnm2xEs7mAouO9f6LNr6jZEK1LSxY3mdWwDwZtxHU3,carboplatin; vincristine,2,128,395
eGUR3Nw4ulQCVlzEyPeIgHw3,imiquimod; triamcinolone,2,4,2663
eGa3V5r7ynDYqBnhE4LL2pg3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; imatinib; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",115,3000,3574
eGaLg.Dxz1AzdE-obzb5HYA3,Progesterone,1,19,4334
eGc8.Eca.2BW80WhvjRf8eQ3,tretinoin,1,2,1037
eGfXrPPBIeR5nxK0ZZWWbFQI1knfyqPiaSNc4.ZIJYZU3,isotretinoin; tretinoin,2,19,654
eGiNd4n1tD-xMDsd5yskycWFUxfeqbxBmTIxETu0sjpE3,Sufentanil,1,1,0
eGikJ6YwlsYT1AK3zjrpbtA3,Zofran,1,1,0
eGiryyhyYRFsAh98EAgihT56ZVpNlL5-C4XfYR9wWG2c3,Fulphila; Revlimid; Temozolomide capsule; Valproic Acid; Vinblastin; Ziextenzo; Zofran; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; lenalidomide; pegfilgrastim; temozolomide; vinblastine; vincristine,17,397,2068
eGlrHES73WqTydzrom0uu0cYBehOzgYBy.ly4cV3Gt7w3,Progesterone; lomustine; procarbazine; triamcinolone; vincristine,5,48,628
eGmgjKVs9.xBsgxfZUy5hxQ3,Valproic Acid,1,7,1781
eGtwYhv8BkbmCg18N13WV2kjqVqUYk6tsaaI0B.lRMMs3,Antithymocyte globulin; Cyclophosphamid; Cyclophosphamide; Fludara; G-CSF; busulfan; defibrotide; filgrastim; fludarabine; mesna; sirolimus; triamcinolone,12,26,121
eGuiKiYZf74tGZn.9ebwb.KEwEKbSyFXqbeU6WJCjdy03,Dabrafenib Mesylate; Tafinlar; dabrafenib; trametinib,4,25,186
eGyb-9KmCyYWtWJgUqbsVHnOXmr.YfQbEG6VzeSyA3jU3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",111,227,39
eHAbXUIkq9ubMTg0Tmqh2JpV4Sd0kY1pBU-jYRpRCm-Q3,ATRA; Aranesp; Procrit; Retacrit; Rituxan; Zofran; bortezomib; epoetin alfa; rituximab; triamcinolone,10,160,4448
eHCMXPCPWwcQp4AZOEuQ4dZzE-dWH2Pxv35cVZ020yXc3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",114,2857,2009
eHI3EUf2lgFJYsgkzZNn4Fn3wCaLiDArghDL9x8q.24k3,carboplatin; vincristine,2,36,69
eHP59ajL7aUHktdiUM1ti3qmOEcd7a-.3KRmM901z7503,Testosterone Cypionate,1,5,1066
eHQwxoOU6oUbF47SsTYqodw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,1648,674
eHRWFRRjOIbTfGILMA-yGGLXPLbiHbSjyPWZtMlnw5aU3,Cyclophosphamid; Cyclophosphamide; G-CSF; Zofran; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; temozolomide; vincristine,12,62,132
eHRbUzfhKMlN4yb22FSWErQ3,IMPACT,1,2,364
eHg7Sh7hQhV8sjYxfAq.e1duYGsX6Qr9ai6cKxJ6iOKw3,Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; Glutamine; Nivestym; carboplatin; etoposide; etoposide phosphate; filgrastim; mesna; pegfilgrastim; plerixafor; thiotepa,14,49,69
eHhtBWmI5cDGaKl9x7kzD8Q3,Ziextenzo; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,48,131
eHjEYHGpo.YkXHApDCn9aevCEBu6YPYEUk-YRSoUcT4w3,Vitrakvi; larotrectinib; triamcinolone,3,14,616
eHkU3BRDUlRKlWIj2cMozg0uWXsN63dm-QdnFuzjk5to3,COPP; Fulphila; Investigational Chemotherapy (unspecified); Valproic Acid; filgrastim; idarubicin; pegfilgrastim; trabectedin,8,43,586
eHpGAelmn0GWrh9YA8xaULg3,Temozolomide capsule; Zofran; dasatinib; everolimus; lomustine; temozolomide,6,46,208
eHr443ol1jjYgk2DvaeKybV2fcblaSeMVEXrc1HpKUXI3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,92,103
eHwChyDCXz2ItaNcOmeSRc1xbTrpSx-YeXqa0YfioHnE3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,111,88
eI1xZ-IsrCoaicROuvfss4bnhuPTWdpNajsWZki8NX783,Cyclophosphamid; Cyclophosphamide; Daunorubicin; Leucovorin; cytarabine; dexrazoxane; doxorubicin; filgrastim; mercaptopurine; mesna; methotrexate; pegaspargase; pegfilgrastim; thioguanine; vincristine,15,260,805
eI2hPWI0XRAVjiBTEp3mccQi0vYxHB3FFnKmJbXyqkdI3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; carboplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; pegfilgrastim; topotecan,11,156,436
eIEpoD6S0ALjpuf76b6QYOy0NGdeUfV3rMFkzmvY5qVg3,Zofran,1,1,0
eILJnxLhI5xhcaWG4SLlObw3,Progesterone; lomustine; procarbazine; thioguanine; triamcinolone; vincristine,6,49,3851
eISWWl31doSZNhilIwjW-Qw3,Zofran; tretinoin,2,2,0
eIV4r0NR-ljONTcxJHp83JynHuehdih.cYShoU3NOqH03,triamcinolone,1,3,0
eIaGz65bSPwaxnK2GkgJQicNEQkybtlYUnfTuKs1cWMk3,G-CSF; Glutamine; carboplatin; filgrastim; thiotepa,5,23,46
eIaRZ0ZYlz6UkKvOldHrzGRitg5ftjYUEOmQm49V5Ao43,Zofran,1,1,0
eIjGsYzAAnZ3NoVJ5-.MR7Q3,Temozolomide capsule; temozolomide,2,2,0
eIlqpT1YQKut9vHBG8A9ukRuPBLodK5FlMwKB8InuPy83,Kisqali; bevacizumab; everolimus; ribociclib; triamcinolone,5,27,131
eIolZzGj-DJ8ZYIYKEtSE8RXROc8EwEqsu5lJwDYnyiY3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; Nyvepria; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",118,1238,104
eJ.F.HEjhe9FeBRGpcVKBZMtm.bSx3GiYpkNRxwxgo6I3,Cyclophosphamid; Cyclophosphamide; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,12,72,104
eJ.zG0fqeNgV6ppw1gSByEPSqFCJtjtJrW9102aqmsbc3,Ketoconazole; triamcinolone,2,12,4472
eJ1H.kxBspnVHsMO2cAZrAz8QbrNaIR.O7rIhJGPVdGg3,triamcinolone,1,1,0
eJ1g0WrXrLMXIyOqjs8gxLw3,COPP; Investigational Chemotherapy (unspecified); dasatinib; imiquimod; sirolimus; trametinib; triamcinolone,7,32,2049
eJ7IOqPGtZoKpI-NkpS3GWT8khdAnWMpYxPNxA8.brbs3,cisplatin; lomustine; vincristine,3,92,385
eJD6Vpuo9wQiCyWH1VGJgvUpw3d4wcxNey0QJO2882Co3,Cyclophosphamid; Cyclophosphamide; G-CSF; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; triamcinolone; vincristine,10,94,308
eJHdMvnRlMmjZKguCcYdKLto5RhekHGjoG63q5xXNrX03,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,84,85
eJHyVkrRQWnCLHqpFiVHhWo2WJ.y52pqwuAk-zJa.mI03,Ketoconazole; isotretinoin; tretinoin,3,3,51
eJIjrCYefWzbB7NKRnJQCLCd2UQEiDnf2AhvxHf.2OP03,ATRA; Daunorubicin; Mitoxantrone; asparaginase; bortezomib; cytarabine; dexrazoxane; etoposide; hydroxyurea; pegaspargase,10,71,227
eJL2ZYJhUdMli6-W0CzXREg3,Ketoconazole,1,2,304
eJPr83vkibn39GzCrak1i4K0saUoo0ME6bBOFetuZ3pU3,Cyclophosphamid; Cyclophosphamide; Glutamine; Nexavar; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,12,65,3015
eJT5GcDCDbp0DYOZpphiojw3,Avastin; Temodar; Temozolomide capsule; Valproic Acid; bevacizumab; etoposide; everolimus; irinotecan; lomustine; temozolomide; vorinostat,11,104,564
eJV0aIYsnAw-CIeLyYsbWWA3,Lupron Depot; Temodar; Temozolomide capsule; Zofran; etoposide; leuprolide; temozolomide,7,105,41943
eJXdC83zNbltZLaQCalLB2B24gOICSw.oYFAZPJDvl8A3,carboplatin; vincristine,2,148,419
eJcafcl.xwNZLeeFduvd1Y-96ttZJqnSphD1kcHU4bP03,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib; triamcinolone,6,32,481
eJj7HMjE5c1jMsEQHFhe2cgAHugL91jMOFlYeNycZ6ak3,tretinoin,1,1,0
eJjqUGccf-SuI84rhHUhOSA3,Cyclophosphamid; Cyclophosphamide; Hycamtin; Temozolomide capsule; bevacizumab; carboplatin; etoposide; filgrastim; irinotecan; isotretinoin; pegfilgrastim; temozolomide; thalidomide; topotecan; tretinoin,15,145,1694
eJq5YplMCafc4rRw.ZwAjzEZQ3qWyHk7YiIiRmqk5RVI3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; Gonadotropin; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; anastrozole; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",117,978,4172
eJxLHaZEGDI1h3LRKoI0KeQ3,Ketoconazole; triamcinolone,2,2,2512
eJzghDhDocluUleV1FGu7eBdxhS.DViGDGZ2gYtTwssY3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Valproic Acid; carboplatin; cisplatin; etoposide; filgrastim; isotretinoin; mesna; pegfilgrastim; thiotepa; topotecan; tretinoin; triamcinolone; vincristine,18,142,305
eK1lZ2rwYxCkArQ7eAzApfgWgHgFw7Z3Ml9v.PLlPDgg3,Cyclophosphamid; Cyclophosphamide; Fulphila; Valproic Acid; bevacizumab; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; topotecan; vincristine,15,177,454
eK2-yRzrLb2hj.Eo5gK-fXdYPOobb21Vkxp1d4SQXwxc3,Temozolomide capsule; Vinblastin; Vinblastine Sulfate; Vincristine Sulfate; bevacizumab; irinotecan; lomustine; selumetinib; temozolomide; trametinib; vinblastine; vincristine,12,749,5294
eK34-26ZnZn5lflpZxoHXE6xprUtZstqKzP6uJ3dGaAg3,etoposide,1,4,1
eK4moB-X3bLCbP.kmz9D9888X0ZY8kHUvqFij6Nyta2A3,triamcinolone,1,5,285
eK9iwEBMPDwGA6P7-KvQquIZrwWK9TW9Ceh2Van3Wsbc3,carboplatin; vincristine,2,144,391
eK9qzfik-QzELVOfXsTjtyvg7CcpK9dCRG9PYFf6VNyo3,Temozolomide capsule; Valproic Acid; bevacizumab; carboplatin; etoposide; temozolomide,6,33,424
eKE-eSa5u8sxsMAXkUiUMpZAbS2npAZCZisaUAp2S21s3,Fulphila; Leucovorin; Progesterone; Temozolomide capsule; Ziextenzo; atezolizumab; cisplatin; dexrazoxane; doxorubicin; filgrastim; ifosfamide; irinotecan; mesna; methotrexate; methylnaltrexone; pegfilgrastim; regorafenib; temozolomide; tocilizumab; vincristine,20,155,499
eKHiT.6D1Fg0FlWe.d59f.fJzk.g4LCv.QpIBJf3kLUk3,mercaptopurine; methotrexate,2,11,161
eKNDXG0LK2hh-AQR2PPV-nnmP-5beg4sPEpIS7xH6KpU3,triamcinolone,1,1,0
eKRoLb7BL.Dsv-au2l9KBpiz9bjJjLAjq6QOu6SFA81w3,Chloroquine; Cyclophosphamid; Cyclophosphamide; G-CSF; Hydroxychloroquine; carboplatin; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,11,164,1922
eKZ2aE3w45YRzOhKwN6sn7pVC0MHzZAsChJi8-a98i983,ATRA; Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; cisplatin; etoposide; filgrastim; pegfilgrastim; temozolomide; triamcinolone; vincristine,11,60,177
eKZt86qBbxmOP.uaSf0vWimcOoS1sagfzmhKtB7ydkTE3,ATRA; Acetic Acid; tretinoin; triamcinolone,4,7,2049
eKc7CD8wxR2oo2WT--bYh9nlph.a8wF4rsAZegRJXKgo3,Ketoconazole; triamcinolone,2,5,1222
eKkpA81CsaOZrRvH5MUjR7-ecp-rILkHqgkFypzQU1oA3,Fulphila; Hycamtin; Investigational Chemotherapy (unspecified); carboplatin; dactinomycin; doxorubicin; filgrastim; pegfilgrastim; vincristine,9,83,432
eKlcyoaP0fr4CMU43j4RpOg3,Temozolomide capsule; Vinblastin; bevacizumab; carboplatin; irinotecan; lomustine; sirolimus; temozolomide; trametinib; triamcinolone; vinblastine; vincristine,12,262,2581
eKpqwhTsWDBOMFp-rxBeoS4JAu3UVh02MBP2lBlUYwdA3,Dabrafenib Mesylate; Investigational Chemotherapy (unspecified); dabrafenib; trametinib; vemurafenib,5,27,148
eKtGBqRGnqyC6sKmM0GBV2V.gQcjJAccx1h30ngzNbj43,Temozolomide capsule; Valproic Acid; Zofran; bevacizumab; etoposide; temozolomide,6,116,1065
eKvEKAxJ9B-tlU0BPnPwQFqrxYmzA52FGqczcsEbn20I3,triamcinolone,1,1,0
eKvPVDXud2MFmzOgyw9PrPQ3,Ketoconazole; Temodar; Zofran; bevacizumab; selumetinib,5,19,353
eKxF7APhpv4ZDDljD9lZSfA3,ATRA; acetylcysteine; belzutifan,3,4,1
eKyZeU3oBkgJocqKmA2SrQQ3,triamcinolone,1,11,1255
eL-tSIuAgw96owYZFwslXUbn-3.03uVXpliyK4YU.vI03,Testosterone Cypionate,1,2,148
eL5c6mf0DOLJwvBuJjBmlOg3,bevacizumab,1,50,721
eLAEH6dMFkuSED3UsFALZwrXTTtrGV5ruQHWIy5B7FXM3,ATRA; triamcinolone,2,3,2689
eLEx.F6Jhy3zyguoU2cSVQGUVZMAA6FH.PP0IV2-ydac3,triamcinolone,1,4,4
eLH6lYUrZil6DZgr1ayb1WXBU2J18oH0NSb5zOmMNfa83,propranolol,1,7,1
eLKuVNd-0tXQXGkXqjZb5yOwBYAsyZhts68hVQ-O01fY3,Testosterone Cypionate,1,4,242
eLYDaneXxP6iLlyzfF00ltyFO.Lr.f4TSPMhp-Pvn6ZA3,ATRA; Temozolomide capsule; bevacizumab; carboplatin; etoposide; temozolomide,6,33,207
eLYgwG8CvvlMlqCNP2B5kqW0PFSXF0MqC-h5TlmaTVs83,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Leucovorin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; triamcinolone; vincristine,13,103,174
eLZxd4DTv4DClZcgvVSLG7rTLenres.nJ1Lh-rC6y4T03,Testosterone Cypionate,1,18,1691
eLc9dNiBMdaYS7zvrljqEe3t-7c27AqhboqXNPRmCYSk3,Progesterone,1,1,0
eLfjhZicI11j4ucfxikYd21H6wNhBw7b-N9XpLZJbSDE3,Cabometyx; Investigational Chemotherapy (unspecified); cabozantinib; cabozantinib s-malate; etoposide; filgrastim; ifosfamide; mesna; methylnaltrexone; pegfilgrastim,10,45,186
eLiBnqT8OtjnFzBV15X1Uuj-3WJEXq7TFTzdkS.kERqw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; AZD6244;;Dose; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",113,3412,2846
eLiG6.0hbwU-5ljD0B4hUh5heq3ipPk3TILjYLt4l6P43,Dabrafenib Mesylate; Mekinist; Tafinlar; Vinblastin; carboplatin; dabrafenib; trametinib; vinblastine; vincristine,9,1053,5279
eLj0SXhZVImBO9b84oVrqHglld3CGYDRjkdLA-AvMH4w3,Camptosar; Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Neupogen; Sancuso; Temozolomide capsule; Valproic Acid; cisplatin; etoposide; filgrastim; irinotecan; mesna; pegfilgrastim; temozolomide; vincristine,17,183,662
eLjiZMccaXCCYBdRZv22Tv-XSt-qbWiujZCT-qWpAW2I3,triamcinolone,1,1,0
eM.M2DOgR8LM4Li4CIb21EoeqIteJ3Bng8vBykUZswPI3,Ziextenzo; carboplatin; etoposide; filgrastim; pegfilgrastim,5,36,78
eM5WtMoiLVe2tAfS5WJJBsQiDTUJsfvRi-NZDPjjgqbY3,Hizentra; Valproic Acid; triamcinolone,3,14,325
eM5s-QPLIcMzLnR9Iiv5DHIcbrPZFHBkTdU8YKV7MxRk3,Lupron Depot; Valproic Acid; leuprolide; leuprolide acetate,4,12,896
eM7AAxn1Bgf9lBLhhXtVO7YgjTO3GhIbZpiMi86f70BE3,carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,6,44,104
eM7d3S7rI02Fq4egHTgK7x.N1XTIy3RwfG8iDMvnWJxY3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,102,98
eMA2aroD3qu4zv3MhND4.zbeQq-.UEGXIT88aJXwO1Lo3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; Glutamine; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thiotepa; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vincristine; vorinostat",126,1178,246
eMH0t2JeQ-ff9bSe7c8vyGp6rRCt75.OsRM5GXp9SFfs3,Gonadotropin,1,4,180
eMIlA2wmFO5zyXwxnm.Z8EQ3,Cyclophosphamid; Cyclophosphamide; Ketoconazole; Neulasta; Temozolomide capsule; Valproic Acid; amifostine; bevacizumab; cisplatin; etoposide; filgrastim; irinotecan; lomustine; mesna; pegfilgrastim; temozolomide; thalidomide; topotecan; vincristine,19,230,1823
eMMJQqNXtG8b38-oyy4MFbA3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,661,168
eMP6f8vb7QcAJpPpukeAZARLCVkobcXUSYpHMakY7Iwc3,carboplatin; vincristine,2,148,402
eMU.lt.-dUKItEuwVEPc9R90k3V1AQFJ5d2Hp5A1Z2NE3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vitrakvi; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; larotrectinib; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; repotrectinib; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",117,1270,990
eMcLQW8Lh8rMdpEfIIaP30w3,Temozolomide capsule; temozolomide; triamcinolone,3,14,47
eMfWBQuGhglbmMYklQ7d5ew3,Ketoconazole; Progesterone; bevacizumab; carboplatin; trametinib; tretinoin; triamcinolone; vincristine,8,241,3687
eMmJ1lB3yqZbIa.QH6rn9UQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Ojemda; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",113,1230,1155
eMs2NnGm924T3P.-WlJNbGSyTbwC0mH.Uy9GHFKhgUq83,IMPACT; Lupron Depot; leuprolide,3,19,2308
eMsQ.3znWa8URkjRS5fvQnxElimzw6OGNB-AoKVRdbZE3,mitomycin,1,1,0
eMvIIkiABCtg-zOIgNP8Y9-HRBuRjZ7.ctb34bNYHB9U3,Cyclophosphamid; Cyclophosphamide; cisplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; pegfilgrastim; vincristine,9,48,49
eN.vL4p.p98AGVOW729xiXQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Lupron Depot; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Testosterone Cypionate; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; leuprolide; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thioguanine; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",122,1794,4606
eN9f9Ypfu5VcvR.-Yymfzp1lx69bZRMbgdLaSQeRrpjM3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IMPACT; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",115,3124,1617
eNA0bbKXEjgXMWisMtutepSiqu6bKcXSrussVoQGfqS83,Revlimid; Temozolomide capsule; Vinblastin; bevacizumab; carboplatin; etoposide; irinotecan; lenalidomide; lomustine; procarbazine; temozolomide; thioguanine; vinblastine; vincristine,14,400,2358
eNICC.KSAZOnTB1keVOFMmEdn6ezhmW0caXmEgbQLzD43,triamcinolone,1,1,0
eNIceMx0f3On8bDha0wrujwBJlsYQRAdqPyDC4oXez9s3,IMPACT,1,1,0
eNKM-OO2YqWaNFuzTRQY5t3eNdwM1x6GkzxcXgzB9nSQ3,Temozolomide capsule; Vinblastin; carboplatin; temozolomide; vinblastine; vincristine,6,60,135
eNLJ.2hbWFtO3kZv1kpU2JTdOw.n8f7wYyq8-GQPAg9g3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; dinutuximab; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; temsirolimus; topotecan; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vorinostat; zoledronic acid",127,2733,1618
eNLgCHs.RYKzjItNNcql9tpzdjZi70j4Q7TlaWxGY2OE3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,88,103
eNObBW6zvMV4V1uonwRI4nA3,Progesterone,1,1,0
eNPOJKuFNBaXsKKwpbKbJ1g3,irinotecan,1,1,0
eNPuyK2KRHivkDmaeGtlQP2SUE-j3TAClLKkDcABFioE3,propranolol,1,1,0
eNWGKvvQqZszdGxVn8BF5PWLvOipdUlSLerPFzcQTWSU3,everolimus,1,7,120
eNd1.8MAyKpE6BgjSuj-LZZrXCi1lrwYgn5Xa8R5mwX03,carboplatin; vincristine,2,134,496
eNdsM0zzuZ268JeTtY0hitxC1w1.4JrnpT8AldpjJR9E3,Temozolomide capsule; bevacizumab; everolimus; irinotecan; lomustine; temozolomide; vincristine; vorinostat,8,160,1187
eNo767hiZBPv6Ng7LW7HSa-FVpWGJvuHQThQPYUFMGd03,Pentoxifylline; Progesterone; Temozolomide capsule; lomustine; temozolomide,5,51,2374
eNrutSLwS17vUkeohT4kL8gATScv0sjHWBjpvIefvJdw3,Sufentanil; Temozolomide capsule; bevacizumab; carboplatin; etoposide; everolimus; temozolomide,7,64,1802
eNu6kVbn3raraxYdWWPJMZZ1.QzrMmP3d4hyCbK1GM4k3,Cyclophosphamid; Cyclophosphamide; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; vincristine,12,122,112
eNuAdEju4C1IpYC6jIaGdcbaLbiZefk1DMPLa8Q1w3h03,Progesterone; carboplatin; etoposide; triamcinolone,4,26,5278
eO.w8I4L7qD9vdb9hn9fGtQ3,Cyclophosphamid; Cyclophosphamide; Temodar; Temozolomide capsule; Valproic Acid; Zofran; bevacizumab; carboplatin; etoposide; temozolomide; thalidomide; triamcinolone,12,87,3599
eO0-FWohgSMU56r0IKvFqdOWwdO6jRPZJNKL0GT6sVGI3,Cyclophosphamid; Cyclophosphamide; Fulphila; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,68,91
eO1Dav099k4Q5Dd7qQ1hw7Fzt4.blh8kq1Kus0fLL.fk3,triamcinolone,1,4,227
eO1fG3df9fDHe0iVY3-pHlwNANIG-7GkSz.vAyXzcvAM3,Zofran; bevacizumab; triamcinolone,3,8,176
eO2nJEef1.jqn5INq1P1N5NVG2dHysRPVb1VUMXjb9pE3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Valproic Acid; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",114,467,162
eOA5P-EToXL1t0SW9G-jfjGvw2R0qCWg7SZ94VDXjwyA3,Ketoconazole,1,3,546
eOCeZWQwCLgjG7wrRfXpWC9H90VFA89ny1Ug0Esa1qm83,Koselugo; Temozolomide capsule; Zofran; bevacizumab; carboplatin; selumetinib; temozolomide; vincristine,8,230,1858
eOEaUZ-6f0vYGBS1s8M-hrw3,ATRA; Apatinib; Avastin; Investigational Chemotherapy (unspecified); Ketoconazole; Progesterone; Tykerb; Valproic Acid; bevacizumab; lapatinib; lapatinib ditosylate; triamcinolone,12,259,3389
eOKbJiB3615HNcOJO9qoZZ5MtDAgq3qhepRP8tpsor6c3,triamcinolone,1,3,45
eON32pCo.HoUvwKwABuC9k0AaH9o1HOJm73f1QD8TIBk3,Ketoconazole; Koselugo; selumetinib; triamcinolone,4,21,376
eOOPu8.vUTXocnirBRuRdL9f5uYStGcUyLwtgkdFx5103,triamcinolone,1,1,0
eOOdjt8lgSBi6XYXdEudXZwu2A9HfsDxEvJCJ5SKyEFY3,ATRA; Temozolomide capsule; Valproic Acid; bevacizumab; lomustine; osimertinib; osimertinib mesylate; temozolomide; tretinoin,9,45,212
eOTkpCsiTZY.ez5KMiPh4KCYO2FtnKRNzxG20-91ybkQ3,Abatacept; Adalimumab; Infliximab; Jakafi; Ketoconazole; Progesterone; Tofacitinib; Valproic Acid; methotrexate; methotrexate sodium; ruxolitinib; ruxolitinib phosphate; tretinoin,13,78,5094
eOZBiue2zcg0y9uVA7P1ivmosbFyk9keCxP7CqTZV-q83,Valproic Acid,1,2,0
eOZfbkbdhkKUEHE7CAIZ8yovNAmgFkNWR0NNhZlsMWwM3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Temozolomide capsule; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; temozolomide; vincristine,12,106,139
eObQeZenILF6knEYcOrhpS0g2Poz.l85hqeJOVzQAkVw3,Cyclophosphamid; Cyclophosphamide; G-CSF; IMPACT; Progesterone; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; ipilimumab; irinotecan; mesna; methylnaltrexone; nivolumab; pegfilgrastim; tbo-filgrastim; trabectedin,18,140,488
eOo0J6gjx8iS2WqihCuFluySJoRl2KEwa4fTgO2P3wmo3,Mekinist; Temozolomide capsule; Vinblastin; bevacizumab; temozolomide; trametinib; vinblastine,7,166,2669
eOxO6GwxcKgewbRy9KNSjLZpiMxxrot7WOiq.fzi8fgM3,Investigational Chemotherapy (unspecified); abemaciclib; bevacizumab; everolimus; lomustine; osimertinib; osimertinib mesylate,7,37,89
eP.fPYXqY-hLTT8I.FsVMNechkpQkVWAFwzBnQRK32qc3,selumetinib,1,1,0
eP49aWZMeY10YuptOL.PurYTx9d0fwKZj.pn2Wdpkm2s3,Cyclophosphamid; Cyclophosphamide; cisplatin; filgrastim; gemcitabine; mesna; pegfilgrastim; pemetrexed; vincristine,9,117,201
eP9H-7gevMgKHDUHzBbvuMxukU3dBnkMK..dFe5T3pak3,vincristine,1,12,33
ePCcDRUsjiniYE3.EIVUejNqzdu1ovhebX.tYYcTI25w3,ATRA; Cyclophosphamid; Cyclophosphamide; Sildenafil; Sufentanil; carboplatin; darbepoetin alfa; epoetin alfa; filgrastim; pegfilgrastim; propranolol; triamcinolone; vincristine,13,30,3315
ePFHyiwjgA6ahc7yaCZSSJF6Y6ZDniA2vG1tl1esFwqQ3,ATRA; Investigational Chemotherapy (unspecified); everolimus; trametinib,4,34,95
ePHPMuYLlVGYZp5t6aUD73NDZAhP9Z7Ig8CqDyHp35IE3,Dabrafenib Mesylate; Mekinist; Tafinlar; bevacizumab; carboplatin; dabrafenib; trametinib; tretinoin; vincristine,9,75,1792
ePSmDro96rkKhP7n-rfvEaMW9MoURX9kEuHe1oFtSvC83,Cyclophosphamid; Cyclophosphamide; Neupogen; etoposide; irinotecan; temozolomide,6,35,161
ePYcF1PnIO8YYXhe6V6OgW.Oe26cpgFsSyO8nd6yTuTM3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; aldesleukin; carboplatin; cisplatin; dexrazoxane; dinutuximab; doxorubicin; etoposide; filgrastim; irinotecan; isotretinoin; melphalan; mesna; pegfilgrastim; temozolomide; thiotepa; topotecan; tretinoin; vincristine,23,272,2261
ePZ.4y3rnkdjRMolAeykVmVkmkfhRerZiiNaOfwhxk1k3,Ketoconazole,1,1,0
ePaEWmh4.eOkJDkWtQZhlug3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",111,345,273
ePd3WFX0cjY.P36SJ.bXJuA3,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Neupogen; Temozolomide capsule; bevacizumab; carboplatin; etoposide; filgrastim; ifosfamide; irinotecan; isotretinoin; lomustine; mesna; pegfilgrastim; plerixafor; sirolimus; temozolomide; thalidomide; thiotepa; topotecan; tretinoin; vincristine,24,175,1733
ePjGBXeLgbcC4EEwZ9NJSWdUxWhdvpuc9nXj-6ACEpjA3,carboplatin; etoposide,2,8,28
ePytl6Ts5NsVCsCq3kAom5w3,Temozolomide capsule; Valproic Acid; temozolomide,3,8,586
eQ6ogd2xx3Lpp9op9G.ysAi5acEhwwlUyagyCRfcELH03,vincristine,1,12,34
eQ9JyxlbmB0nKwp4hXsn8BDNDLVovXI9GWGgBKQ0I9yk3,Temozolomide capsule; temozolomide,2,9,250
eQBfUoYWZ5g-I7bukKFQz3OEpvdi12HWMc1ANsmgCtak3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; Vinorelbine; Zofran; etoposide; irinotecan; temozolomide; vincristine,9,59,464
eQChxF.KBZ69hVf-5dWExuQ3,tretinoin,1,1,0
eQLhLDZbJHYj7KExXrnsfP-IzAplxu4KtRee4mRCPgJQ3,Vinblastin; Zofran; bevacizumab; carboplatin; irinotecan; triamcinolone; vinblastine; vincristine,8,340,1832
eQO8xRAI9dSVLXyeOrDFD6RmLL-93B6fhqNSaOHabPDA3,L-carnitine; Valproic Acid,2,89,3042
eQPPtciPVCyv2loETpNuutg3,G-CSF; Neupogen; Testosterone Cypionate; Ziextenzo; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; plerixafor,11,70,1748
eQSB0y3q.OmvN40Yhg9.eCBk5-9c-Qp-FT3pBWoSGuL83,Temozolomide capsule; etoposide; nivolumab; temozolomide,4,16,196
eQZvKm7kSrIxucQ68Z8YSOiz-684gmhSYSxH7MACIK9k3,Cyclophosphamid; Cyclophosphamide; Emend; G-CSF; GM-CSF; Granix; Leucovorin; Temozolomide capsule; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; irinotecan; mesna; methotrexate; pegfilgrastim; temozolomide; thiotepa; topotecan; triamcinolone; vincristine,22,258,391
eQa9sxsZNq8sUVSUdBeeGWAVafjFm33bl6QWHsZnHl0U3,triamcinolone,1,3,4
eQgj6jzQgzoN.hWfTyt1l.6.Q260Qpo8EJFC0KedzytQ3,ATRA; Hizentra; Valproic Acid; imiquimod; triamcinolone,5,41,2837
eQgpJ9Ku5Wb28ERvip6Zu.V-7DxQBGMCssJhbK-ck3BA3,Investigational Chemotherapy (unspecified); Ojemda; carboplatin; tovorafenib; vincristine,5,156,2684
eQlI3nuQMXiXGCrtwkmgTZj7WR-sYOhn8FSrG4lrLIrg3,Cyclophosphamid; Cyclophosphamide; carboplatin; cisplatin; etoposide; filgrastim; pegfilgrastim; vincristine,8,115,603
eQrTkKkDzHh1iOJX60CdW5nbymS623GdFVRmWFd3AswY3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Acetic Acid; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; Avastin; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; GM-CSF; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",115,467,757
eQuQCeRVXavIvrXYe9g7SoNCvGL9BsrkLvEILv8QI9m83,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,83,116
eR8c1MXwdFIjEouO3hImN.kCxGCOjP2k888hbCtGMiPo3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; vincristine,13,139,148
eRCa5jxutp2YYmI4xRFZWEvBhENVCe8OeyX59IFLDBVk3,Progesterone; cabergoline,2,8,456
eRDtK6OGvKP6S9IQZXXhEs5dzRfNcRadM8.3KbArdwXM3,triamcinolone,1,1,0
eRKMYoipapjbgl4CUM2y8EIN3mP1kNMlb0scjDqUQPRs3,Progesterone; carboplatin; vincristine,3,54,224
eRL4HRaZ01yqmg6gziMvgylCMXh7.i-mVvxArsOXPxXQ3,ATRA; sirolimus,2,21,933
eRLBvOv4dIREH7o0jOCKqFskQ1eFGaRojdgt9D4wE6-U3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Nivestym; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; nivolumab; pegfilgrastim; thiotepa; triamcinolone; vincristine,18,146,1343
eRLZ7tssooUsQBsv84H8Lnb.52gG2ykUy3n.by8aagGY3,Progesterone,1,5,683
eRNmJ4DgS.v0udG6Z9-6TKw3,Avastin; Investigational Chemotherapy (unspecified); Ketoconazole; Temodar; Temozolomide capsule; Testosterone Cypionate; bevacizumab; lomustine; osimertinib; osimertinib mesylate; temozolomide,11,108,383
eRRN8Kmro1pfjgvi.b5dr7w3,Testosterone Cypionate,1,11,1743
eRSbE4lkbrxwQikJxYiM0hg3,Ketoconazole; Temozolomide capsule; bevacizumab; irinotecan; lomustine; temozolomide,6,109,1492
eRSfV-G6qwa0H-dNBe4n-YP9bLaB2yIyf6T4chaIJd2k3,ATRA,1,1,0
eRSs-Vc6TcXWhz8FJw4XPsv-FURqeEIOhCljvXoqECio3,anastrozole; cisplatin; lomustine; vincristine,4,99,406
eRTOFjDpvUNZc6vdbNpjcoCRYeC1BF2-MEmhYCOQDypk3,Cyclophosphamid; Cyclophosphamide; Fulphila; cisplatin; filgrastim; pegfilgrastim; vincristine,7,68,160
eRUowqqCIIYzwyZIIOKUbb35k4sfiCguALr5M-Gjowv43,G-CSF; Rituxan; filgrastim; pegfilgrastim; propranolol; rituximab,6,37,103
eRVGKdHgawvAIxS2kSoTHNavYmOO.uPW2oUmTLDOn84g3,ATRA; Antithymocyte globulin; Cyclophosphamid; Cyclophosphamide; Rituxan; mesna; rituximab; thiotepa; triamcinolone,9,20,39
eRbczFZBsl7LkjhE6vNXQVTAxywfnxA8Syvy6894ERfA3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; letrozole; mesna; pegfilgrastim; vincristine,9,90,2045
eRdymQ2Td2o.VRrTXytsKHQ3,Acetic Acid,1,1,0
eRf7jY282R8x113z5xRvUin.KbLzkXhEAIxVI8oeSMc43,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONC201;;; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",111,2308,323
eRgfvO7qvzo.MJ8dQBdRZVZNzxo0u.KpCbQUZ0FWQEec3,Acetic Acid,1,1,0
eRqa6qVu70zJKQPO3zM-6KQ3,Cyclophosphamid; Cyclophosphamide; G-CSF; cisplatin; etoposide; filgrastim; mesna; tretinoin; vincristine,9,117,1692
eRrE8si4nDSjTPwUEbn5iKO4Xp3Bif4qUZJUirRT1Ejc3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,226,48
eRuN5rqbt2Jn2i5jHOr2A0jHxezV7qiJWvG72ctE1.U03,Temozolomide capsule; temozolomide,2,2,0
eRwMOZvr9NYQO2Lt4lE8DovaqLo4Roe3dOss-lR6E23I3,Valproic Acid; triamcinolone,2,7,2497
eS-gckG9y6qolPnmK7DsWAA3,Progesterone,1,2,115
eS.cJ5l9iaqkIl3JlcDNwTWLZsuhhCaAj.Yda5ai9yeU3,Testosterone Cypionate; Testosterone Gel; Zofran,3,13,1309
eS1.8JBZoj.f94.f2k7TMdA3,G-CSF; carboplatin; etoposide; filgrastim,4,24,76
eS9pttZiu0L0H9b0obTKJjA3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Progesterone; Rituxan; Trexall; filgrastim; methotrexate; pegfilgrastim; rituximab; tretinoin; vincristine,12,181,2043
eSIEiNfVA-IuXTzEDPYzIqyVnDsX2sb.5n4i5WIorxP43,Valproic Acid,1,19,111
eSIWi8xSQhBkwHnOSjNF.akk.GKsA-ZWr35RmvxU8IbM3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Afinitor; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Dasatinib;;; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Iclusig; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trametinib;;; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Verzenio; abemaciclib; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; ponatinib; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",119,439,703
eSOLVEwyaulwhLH160I.nYVtSiLm7BhwMtswwRB7GXyc3,methotrexate; methotrexate sodium; triamcinolone,3,68,3577
eSUS-B1Z41pxEXmotq3GFmqDANZ8eVhzdmXBA01di6uQ3,Lupron Depot; leuprolide,2,74,933
eSYQRp2kzmr3r3AWjSe1SXx-8aKGfxqtgGjEw8jMscG03,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Neulasta; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; sirolimus; sunitinib; sunitinib malate; thalidomide; thiotepa; vincristine; vorinostat,19,139,317
eSbq1zT6OUcf3q14DQs08ig3,isotretinoin; tretinoin,2,2,0
eSbqtqjXW1.M15i.uBZ18KIgbAa8ifYiFu3Y72axXcOk3,G-CSF; Glutamine; Valproic Acid; carboplatin; etoposide; filgrastim; ifosfamide; mesna; plerixafor; thiotepa; triamcinolone,11,53,1420
eScA-xXW1rhj4mUeUpIjNIl82E.CkJbekj6JQD54L8a83,Oxytocin; acetylcysteine,2,2,0
eSew70bo29tjiRN.KbIA--IbQvq2wTqI6963o2NT0zuQ3,Cyclophosphamid; Cyclophosphamide; G-CSF; Neupogen; Progesterone; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,11,84,128
eSgTsw8LaH6FQrXl2QmrjeCeNjzSTAE5YpX2g.PrWceA3,G-CSF; Temozolomide capsule; Valproic Acid; bevacizumab; cisplatin; etoposide; filgrastim; irinotecan; lomustine; pegfilgrastim; temozolomide; triamcinolone; vincristine,13,127,519
eSknZjB8g3qH0hdqs97VQ8IjPZHc2R1VWFwFkq2g9-YE3,ATRA; Hizentra; Investigational Chemotherapy (unspecified); cladribine; clofarabine; cytarabine; nivolumab; trametinib,8,46,65
eSn6obMfKfBUpbkh.ZGqYUxcSm-7ge5iViv8lVMz6ByE3,methotrexate; triamcinolone,2,33,1070
eSzWydmzn7GifBBo79ek2SN5UDhEsHkuI.ti5viD.yaM3,Testosterone Cypionate; bevacizumab; triamcinolone,3,21,1532
eT.dSdnyvF9hmm2YZxF3pJjdi1EqpbKig.K7YZxBtmeI3,triamcinolone,1,1,0
eT2mjLcUMLuuyYL-XrDDiRN1GAv9m1RATe9DQGWqOdxo3,Dabrafenib Mesylate; Mekinist; Tafinlar; Valproic Acid; dabrafenib; trametinib,6,45,708
eT7r7o7Y-5bCteIpJYSGGiEQ6UG1NayoXNsSYFgFbY283,Antithymocyte globulin; Cyclophosphamid; Cyclophosphamide; Daunorubicin; Investigational Chemotherapy (unspecified); Leucovorin; Venclexta; asparaginase; azacitidine; busulfan; cytarabine; defibrotide; dexrazoxane; etoposide; gemtuzumab ozogamicin; mesna; methotrexate; thiotepa; triamcinolone; venetoclax,20,123,737
eTC88ABMeLI5r47wqzC2n9-o8VHYTBjsqvCaG2ArNgWU3,Valproic Acid,1,3,0
eTHWIlQ2uWnkFbLvei3vL5opgdgoHj.i3plZXQDtvevs3,GM-CSF; aldesleukin; isotretinoin; tretinoin,4,35,91
eTHueHegsu5FIlV2BEHhXvjvwHjVhFIEvk4KiYh0Prpk3,Triptorelin Pamoate; triptorelin,2,12,435
eTNPd9WHzsVIKowqe-CAUizzOYf7I12HMQznBD1YrUsI3,Progesterone,1,3,12
eTOmqmugwh4Iz4c-ftORv5rcMGPMz3Qp21J8dJYJ7bEY3,IMPACT,1,1,0
eTbPDFT32J8vhsJ1G4tNhTw3,Ketoconazole; Ziextenzo; carboplatin; etoposide; filgrastim; pegfilgrastim,6,31,3389
eTdMz8K83IvMTMIrPuj4pYg3,Ketoconazole; Pentoxifylline; Valproic Acid; Zofran; triamcinolone,5,21,922
eThBeNCQSZ9OO536U0D5boDt.FmlJ1EdJaITGxBJwhNw3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib,5,49,512
eTiYOlSaWrr93U4Kvf5MiV9z4mTrj4wFexuWRTZsZC183,anastrozole,1,1,0
eTqnU-d-7IWa5zWPVnK16vaZq0qUDfQUZB.5d8kbiRlA3,acetylcysteine; triamcinolone,2,13,806
eTsTC65b18h50a948z714Fw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vorinostat",118,3308,4410
eU-tDgWSPI9XdFc.Gm8mJO1tsbn0VYb6hLFPdhbwgsfU3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Ojemda; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thioguanine; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",124,842,4402
eU2j20h8UMQp0SgIdqmksvA3,ATRA; Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Progesterone; Temozolomide capsule; Vincristine Sulfate; carboplatin; cisplatin; etoposide; filgrastim; isotretinoin; mesna; pegfilgrastim; plerixafor; temozolomide; thiotepa; tretinoin; vincristine,21,116,391
eU4DOtcZarQIcAxo2UrRcTO24icbAhNZP487MhVHJn4I3,Placebo,1,2,0
eU6LIFcnfo755DIKFSyp2orb4sIKFkQXSHIc6rN42gLI3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",112,781,146
eUBg.w.SHHv6GC0nKKwkXnkcIcOCElDcoJVL0a50qTMM3,Ulipristal Acetate,1,1,0
eUDIsBgVyq8-DrZH6T5hKq.hCtdhtZgrGTnxFdk3wLQ03,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,10,236,269
eUFS4hKO-grXh72WvK-5l0TFbD0sV2SMysYY5JpxOR-A3,Temozolomide capsule; bevacizumab; lomustine; propranolol; temozolomide,5,69,1196
eUHHjV1mcn0-lDxFMjnaynHOq1T7PzQEApMvApSBnkW43,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,10,66,78
eUI6GidGP1HNFxNPUyqtVbg3,Emend; Tadalafil; bevacizumab; carboplatin; imiquimod; irinotecan; lomustine; procarbazine; thioguanine; vincristine,10,197,3889
eUOq58WmQ5ZR.Me1TlQeMV6EUnY5G756nZZmuXttdIuc3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; Glutamine; IMPACT; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; plerixafor; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",120,152,156
eUUVCWDTZbQdZ2ERSsRGOJtialSFhnnN85pM-Uz92kJg3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Lupron Depot; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Ojemda; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; leuprolide; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; tovorafenib; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",123,2982,3452
eUX..BZ1SzUnhCuBnhSvkzxkWWcsUrJ9jmNcnlYJaFlo3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,110,0
eUb609.gqZM78afGky4DeG73r5XaqYgASyhl0URYdswY3,Cyclophosphamid; Cyclophosphamide; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; triamcinolone; vincristine,11,235,1123
eUf3S1840gZ8S3TKP5fHcPaiqNDmy8PWyLzVIN5vzQHA3,Dabrafenib Mesylate; Mekinist; Tafinlar; Temozolomide capsule; dabrafenib; temozolomide; tovorafenib; trametinib,8,18,709
eUlE2LOiGT7qFeOKGMZNz3NvCyysSqDX4II4Ccw64iSE3,Temozolomide capsule; bevacizumab; lomustine; temozolomide,4,18,272
eUmlh.9Ww5TZa5ROkB1cOae2bljKXqIgZjKPBhpte6vw3,Cyclophosphamid; Cyclophosphamide; G-CSF; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,9,87,118
eUrZds1Qv9auvABgknfWhE4L6HjEog5w0F..2kD7f5K43,Vinblastin; carboplatin; vinblastine; vincristine,4,192,363
eUrpqOhrQdVFf0ydL8Mtq6cOgzeq311wa5gOYKXLLPYo3,Temozolomide capsule; Testosterone Cypionate; Valproic Acid; bevacizumab; lomustine; temozolomide,6,119,2759
eUs753GDpOnOsSdwv0mwl5bitrI49bHvLKASqF88nqnw3,Dabrafenib Mesylate; Mekinist; Tafinlar; dabrafenib; trametinib,5,94,1358
eUtCa2f82K06zOWBlDP.QrcxiK.s9p-sePqghBDmWElo3,tretinoin; triamcinolone,2,2,13
eUulMeCZG7-KidtZ1pwUWpwg98ghVuUBIPMEBvbUEFaM3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; triamcinolone; vincristine,16,165,169
eUvz3TyaZUAIKsGQUbfDGIQ3,Valproic Acid,1,3,2015
eUy16knZcL9qt7au0A8GPBAoFnftDsvvLuH1mwgM6NPk3,IMPACT; Investigational Chemotherapy (unspecified); Temozolomide capsule; abemaciclib; bevacizumab; irinotecan; temozolomide; trametinib; triamcinolone,9,56,1095
eUzqpXN2OrTMx58PQjOvcLuwVgBqKZ-gxyn30NYeQM6Y3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,10,123,194
eV5Ws5ddqmXzroWYmEN.XrA3,Cyclophosphamid; Cyclophosphamide; IMPACT; Ketoconazole; Temozolomide capsule; azacitidine; carboplatin; etoposide; everolimus; temozolomide; triamcinolone,11,49,1065
eV6RGTKRyi3GEStyzyxEwunM3V-1sqrrQ8MAfRI3JksE3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; thiotepa; vincristine,14,108,145
eVAxzXncqGJrwafEs1EGUww3,bevacizumab; carboplatin; etoposide; filgrastim; irinotecan; lomustine; pegfilgrastim; vincristine; vorinostat,9,45,603
eVK3WM85NFEpSZoSJ9LJh19bf3WPjwB22-d1TY6lnSaE3,carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,6,56,126
eVLje6pLUpRcd8AwkWIqqGunXgZrcAXvUha1Hul2I2983,Valproic Acid,1,1,0
eVM12zRRERbzH-Luirb8As1J6oUsl.Ej004gkUDRIt1Y3,Valproic Acid,1,1,0
eVS7yt65kHokMSWB56V6ZKqSppidf26ULGYb02B9ATdQ3,Valproic Acid,1,1,0
eVdki--c5lK2FZ9matCr5wFKcum--ngT8ygCvyrRtezw3,tretinoin,1,2,1
eVfAU2rjBygqL9i84lN3jAOeO9XVEujdjtVCCzSJ9XB83,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib Mesylate; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Lupron Depot; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dabrafenib; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; leuprolide; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vincristine; vorinostat",117,6101,3352
eVfIaQtJXnWv4ZX7qD8yN0A3,Ketoconazole; triamcinolone,2,5,1031
eVj8ly9081aCRMaSAveaYw08V3qqeGlKyeywyIPVkSqk3,Testosterone Cypionate,1,1,0
eVqU49SQNM6zE7mMKgj82lYa8EMo6Fpgh7Fhe5AczU943,tretinoin; triamcinolone,2,2,226
eVvGlY04JfHlbdS3NYINlRTuDlO6.uTRfPMfPRCKnEYU3,Cyclophosphamid; Cyclophosphamide; Nyvepria; cisplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; ipilimumab; nivolumab; pegfilgrastim; triamcinolone; vincristine,14,192,342
eVykNSgbssvQTBnaF2u-UsFSET.wtsIfozMLSVehG9nY3,Emend; bevacizumab; carboplatin; etoposide,4,25,348
eVz2ClC4AeKUJnGGCrX1x3hUCFem7kFo6ZFX0-ZldtKs3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Zarxio; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,17,168,197
eW.XhFEDvm7TmP266ozAy5GN222rq2wj8q1C5mV2RrQk3,IMPACT; Testosterone Cypionate,2,4,639
eW0q1jXkHAmqhUL6II4FZhQ3,Temozolomide capsule; Valproic Acid; bevacizumab; carboplatin; lomustine; nivolumab; temozolomide; trametinib; vincristine,9,155,2029
eW3YVE6L9wHfbzT-001G-rZUMbLZnyUcwg7jsInvDeoI3,Temozolomide capsule; irinotecan; temozolomide,3,4,0
eWBGpp.5I8bHpX2xpA.4QY6QFbUe2zv2b6UXGRcFgak03,ATRA,1,1,0
eWCxOWEOIXcEmI4FOznxObQejxS5uT242kdiTxkMbOQ43,Neulasta; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,32,42
eWEOHQswhzEN.D-xFceGLk10GxcJ5bdQLX.hmlitjDuw3,etoposide,1,4,29
eWI-j.nDB.S5E7hFa8hsCcg3,Temodar; Temozolomide capsule; Zofran; lomustine; procarbazine; temozolomide; vincristine,7,62,947
eWIk1g4UXSd0oJufotV3CWht09tf89CfYktav0KOjRmg3,Cyclophosphamid; Cyclophosphamide; Nyvepria; cisplatin; filgrastim; pegfilgrastim; triamcinolone; vincristine,8,94,289
eWR67boqfqhKKGfMspuN.kOJBU4eonyENquxL8xx8B9w3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; aldesleukin; busulfan; cisplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; isotretinoin; melphalan; mesna; pegfilgrastim; topotecan; tretinoin; vincristine,19,119,358
eWTnN6QUtorIyaBKU.HtRxcKe.k0MSg0Ya8jtT4.0ru43,Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; GM-CSF; Glutamine; Neulasta; carboplatin; cisplatin; dinutuximab; etoposide; etoposide phosphate; filgrastim; irinotecan; isotretinoin; melphalan; mesna; pegfilgrastim; temozolomide; thiotepa; topotecan; tretinoin,22,193,1341
eWWV9tqi5osn7z.0t9gQQ0GLzMS4QvYY9cHMA-cru64M3,Cyclophosphamid; Cyclophosphamide; Lupron Depot; carboplatin; etoposide; filgrastim; leuprolide; pegfilgrastim; vincristine,9,32,899
eWZx.wrK8562PJv1mo60Xdg3,Cyclophosphamid; Cyclophosphamide; G-CSF; Leucovorin; Progesterone; Zofran; asparaginase; bortezomib; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; mercaptopurine; mesna; methotrexate; pegaspargase; pegfilgrastim; thiotepa; triamcinolone; vincristine,22,140,2821
eWbhItdfTTCrBdW26ETRi44OJDElXbuxFv3zwPBz1-kM3,ATRA,1,2,0
eWdTcXzbUPKfWVHj.LBbjXT-M1LNPAvOZ3J4DuyTCh1k3,Valproic Acid,1,2,0
eWdl0XauwkWNliQFvNP1-hyvS9NjxsN.SzQJE.fPSZJ83,Cyclophosphamid; Cyclophosphamide; G-CSF; anastrozole; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,10,85,1040
eWgSwYdYtdM26UCg8EHNCs.E9UyiH3MOTj8Ud.uMQv583,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",114,4393,4276
eWgnPtG2iAcnzADEX8-9csg3,Temozolomide capsule; Valproic Acid; bevacizumab; irinotecan; temozolomide,5,166,2444
eWhKzNU-MAvM5PcM5BWarYEMDNRO5xgsXK3D5GIWC2gU3,lomustine; thioguanine; vincristine,3,6,16
eWm56Y-CRPqdF1HLbLf0Huk4GXP-Vm40IkSB64YFViOw3,Valproic Acid,1,1,0
eWuKLCY5NXRjj9tt5FTbx8y19kpG7u.brMun7wd2Q8383,G-CSF; Neulasta; carboplatin; filgrastim; pegfilgrastim,5,41,390
eWyMqudBNcY5AuA.OgM2cLOLJrrhg7GmzfJDXs7WEDIQ3,Investigational Chemotherapy (unspecified); Ketoconazole; Temozolomide capsule; Valproic Acid; lomustine; temozolomide; trametinib; triamcinolone,8,31,257
eX0jPiKs36K9AC7YJOvBKDgKDpw0.cNb1fHvKVpAbRu03,Valproic Acid,1,8,1776
eX17z3DHzS0AG8mn.rhGyUA3,Temozolomide capsule; bevacizumab; everolimus; temozolomide,4,34,172
eX1yijWp8hfFTQqNQQMglm9wJW562AAfzYLpC00v1trQ3,ATRA; Cyclophosphamid; Cyclophosphamide; Daunorubicin; Emend; G-CSF; Investigational Chemotherapy (unspecified); Leucovorin; Nivestym; Rylaze; asparaginase; azacitidine; bevacizumab; calaspargase pegol; calaspargase pegol-mknl; cisplatin; cytarabine; dexrazoxane; etoposide; filgrastim; gemtuzumab ozogamicin; irinotecan; mesna; methotrexate; pegfilgrastim; plerixafor; sorafenib; temozolomide; thiotepa; topotecan; triamcinolone; venetoclax; vincristine,33,353,570
eX5nyLzQH0PWLAleHGHYK6g3,leuprolide; triamcinolone,2,2,4285
eXKO4PpIocs0-KWAvpEDnDHX8QkBLlSWsse5Yg3Z8y8c3,Temozolomide capsule; bevacizumab; etoposide; temozolomide,4,22,383
eXPe6TNRLluSnNcptVo3qMw3,Lupron Depot; leuprolide,2,5,240
eXYax6pEWjruzsBWNmWEnc6x-7X8f7ZgcjeV4efa6gOQ3,Ketoconazole,1,1,0
eXdEVvOs091o4-RCug2.5hA3,Temozolomide capsule; Zofran; bevacizumab; lomustine; procarbazine; temozolomide; triamcinolone; vincristine,8,76,661
eXehiby-mTEgmTOeDcC6bJzpZtp.2zE.VOVvXV963H0Q3,Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; GM-CSF; Glutamine; Neulasta; Nivestym; Ziextenzo; carboplatin; cisplatin; dexrazoxane; dinutuximab; doxorubicin; etoposide; etoposide phosphate; filgrastim; isotretinoin; melphalan; mesna; pegfilgrastim; plerixafor; thiotepa; topotecan; tretinoin; vincristine,26,268,714
eXfYuoV3Hsc5gZ6v2zXW4NHHJLrDTI4yJ9m41o2PuuIw3,Temozolomide capsule; bevacizumab; irinotecan; temozolomide,4,28,84
eXggf0sWjCKJv5p1QBGhZ4A3,lomustine; procarbazine; thioguanine; vincristine,4,44,356
eXlf.DOPco1VOCWMA-8EgIv2W9GvCRMxxcUMzfCB1GW83,ATRA; Progesterone; Vinblastin; Vincristine Sulfate; lomustine; procarbazine; thioguanine; vinblastine; vincristine,9,59,5137
eXnzuKb7m14U1tcLfICwETX7Gs0ok.FRxG4QodMdhoPg3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; Zofran; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; irinotecan; mesna; pegfilgrastim; temozolomide; triamcinolone; vincristine,15,243,1424
eY2Nc1kYlqNgsqoHp5-K64Y.zrLG0zPoGjxH2rzl4sGc3,triamcinolone,1,1,0
eYF67LHZfLyeDt6LtT3BsNGAlPYLIUKj2fI3jmD0eRo03,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Octreotide; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; propranolol; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",119,218,3218
eYGFsSBBvLE42MCxTjOOnkSKuJDJ.daWZA8.tx7uHxB83,Valproic Acid; Zofran; carboplatin; vincristine,4,223,650
eYMymNQfN1v-sNIUnGNXadl5yNOqHz57.6gViNkI0Py43,ATRA,1,1,0
eYROUgFaB-zdTxO1btROsKcBrM82Tn6gPH3QerxtbAFA3,bevacizumab; carboplatin; vincristine,3,160,539
eYRpFwaKUgpEiV0Vu838G-g3,Valproic Acid,1,9,2226
eYSPtwJM2y5ugNFVlclP6FvVpHYwznwcsl1QRONCtl7I3,Cyclophosphamid; Cyclophosphamide; dactinomycin; filgrastim; mesna; pegfilgrastim; vincristine,7,100,146
eYTZwRnouPVMzZ1WGLzaOGSOjfHZ6wSCuUKw.-5jVIHA3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Ketoconazole; Progesterone; Temozolomide capsule; Valproic Acid; carboplatin; cisplatin; etoposide; everolimus; filgrastim; irinotecan; mesna; pegfilgrastim; temozolomide; thiotepa; triamcinolone; vincristine,21,184,1146
eYWhre0a-7rjXh5uI19I9Kg3,Adalimumab; IMPACT; Ketoconazole; Valproic Acid; triamcinolone,5,58,3647
eYZirislzOlau388wo6NgZ5c79oXVOwvHsq1ybrA3lEk3,Cyclophosphamid; Cyclophosphamide; G-CSF; Neulasta; Temozolomide capsule; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,16,204,371
eYipZ940phf9RSPuHQwSE-sVrAyX53jsaC5V3z.IJ4Ic3,Temozolomide capsule; nivolumab; temozolomide,3,27,283
eYk0bjeeOpQ3bp.3fBGAGbg3,Sufentanil,1,1,0
eYlbUel.GA.aEXZqKcMXckuzHvXJTwtioNOydeovCXBo3,Gonadotropin; imiquimod,2,11,3087
eYoeitl8.sX7Sq6n9mealQ5LcSnLd1jXCzqkkQpkVSYE3,Cyclophosphamid; Cyclophosphamide; Neulasta; Temozolomide capsule; bevacizumab; cisplatin; filgrastim; gemcitabine; irinotecan; mesna; pegfilgrastim; pemetrexed; temozolomide; vincristine; zoledronic acid,15,86,161
eYqnDS3Knfkpg4Ota16BBQg3,Valproic Acid,1,1,0
eYutMICMGikiJulG3SwYrvg3,Glutamine; Investigational Chemotherapy (unspecified); cisplatin; filgrastim; lomustine; pegfilgrastim; vincristine,7,57,149
eYx1jGkEk2899O7kxpPRl0BsqHJl9M4zaeIn.JY56C3I3,filgrastim; gemcitabine; oxaliplatin; paclitaxel; pegfilgrastim,5,13,1
eYxhhPKgwzbAyZEWboKH14OMTn8c6x1FCNQTxILJbGwU3,IMPACT; bevacizumab; larotrectinib,3,17,151
eZ0Rgra3zyyug4Mtx9f-LiA3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; cytarabine; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thalidomide; thiotepa; topotecan; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vincristine; vorinostat",123,375,2212
eZ4paYUpMkVBqQzF7wp8Qsg3,Chloroquine,1,1,0
eZ5pumvnGuLWxcUmzM..3pt9d3FVVeOyJY4tOy3Menzc3,Ketoconazole; Valproic Acid,2,2,1810
eZCRq8Zp3Wbq6dAdPvSByl89jjQUaKFZD6spfedIxko03,alpelisib; everolimus,2,32,509
eZFrCOyefnm7eWa.Mo723Y4aAeZoResk46qpBExAU6Bg3,Progesterone; cabergoline; triamcinolone,3,96,2834
eZLG94VzAO.C01RKTwdOEXvOHNbyn6rS0HUNP-9rGVvA3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Valproic Acid; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; temozolomide; vincristine,12,93,124
eZOEFABrknOtVxIIoh9cz.v.Dr6N1D1bhJl33IvUAd2A3,Acetic Acid,1,1,0
eZPzzZCT6N9WczQR4lvvAIQ3,Progesterone; Temozolomide capsule; Valproic Acid; Vinblastin; bevacizumab; carboplatin; lomustine; nivolumab; temozolomide; vinblastine; vincristine,11,278,1624
eZQbOazL8NHG4qf-doLWKC77HDQD48rmJtbpFeF2Rshg3,Valproic Acid,1,3,22
eZY4FaxsbrqGixEZnQ-4nq6ezReaUHIiHRdDMAXhTfeg3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",113,561,2360
eZdbVYrQhrGcq5FP.F7fYeEhk.HDHpu0caR4IlewxzeA3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",112,676,336
eZgb9DoPpP.T1ae6KJaL0Ww3,Leucovorin; Neulasta; cisplatin; dexrazoxane; doxorubicin; filgrastim; methotrexate; methylnaltrexone; pegfilgrastim,9,75,183
eZi-qCnTv1cZNwwwO-hmzVLK9oaqiRytTYD78m.pD-hM3,bevacizumab,1,10,59
eZkr5mp8aQjKHPXuMg9l-Fw3,triamcinolone,1,1,0
eZmROm8FCux9FtmX.RfH70Q3,Temozolomide capsule; bevacizumab; irinotecan; temozolomide,4,140,448
eZnXVIumINEtg6g5Mazrv6H6UyWm2XlpqrcFxQdr1KXI3,Cyclophosphamid; Cyclophosphamide; G-CSF; Nivestym; Temozolomide capsule; Ziextenzo; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; ifosfamide; irinotecan; lomustine; mesna; temozolomide; vincristine,17,146,1131
eZyQkptTGp.dptdsvACuG6CLsHDOfdnBWgq7W1WwGwbE3,carboplatin; vincristine,2,166,483
ea3PAYRaZFoU1AWI5w-Jl4UcKDziyjOy0.NEHlehEt7M3,Cyclophosphamid; Cyclophosphamide; cisplatin; filgrastim; lomustine; pegfilgrastim; vincristine,7,92,377
ea6c7HFZdGanu5YhptW9j7A3,triamcinolone,1,1,0
ea7.BY2IsWUxN.gxghVKhhlRkzfe3OuuYZjizsqENTnE3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,11,111,82
eaArEFwmzP66qlnnGwzrJTTqHjlJfxKFDtxm2x9edI8g3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",111,1770,357
eaDeLWioAeNW-1hYW0Qh5p877xN8olNj36YmDEVsT4xg3,triamcinolone,1,1,0
eaE0LekhREkzurWxunzfcQGT2wzoHAgkIlNcj501-SdM3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,341,84
eaIYNtrZhTPuy7Cqa2G.pLxZO5YnIHiSezsxSoKNKzxY3,Lupron Depot; Vinblastin; Vinblastine Sulfate; Vincristine Sulfate; Zofran; leuprolide; lomustine; procarbazine; thioguanine; vinblastine; vincristine,11,31,421
eaQt2J0ZXj-J8zZWa2pS-uQIVCGkHesMZT8A4ylVjkYA3,Investigational Chemotherapy (unspecified); Ketoconazole; Vinblastin; carboplatin; tovorafenib; vinblastine; vincristine,7,141,3023
eaVAJ-fsOpIWRjAYnXt9DV-Kl7FwurB5vdxLJ7SirniY3,ATRA; Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Nivestym; Temozolomide capsule; Valproic Acid; Zarxio; Ziextenzo; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; irinotecan; mesna; methotrexate; pegfilgrastim; temozolomide; thiotepa; triamcinolone; vincristine,25,198,781
ead65Eb3.6MRLYUmaS8Ix24vcK.HV0n1elzIxHq8HZK83,Temozolomide capsule; bevacizumab; temozolomide; triamcinolone,4,28,402
eamm0UDVf23wdXdkGsrlkzJMgLzC7mmhE7UVOK6mFLb43,Dabrafenib Mesylate; Mekinist; Tafinlar; carboplatin; dabrafenib; triamcinolone; vincristine,7,188,1344
eanHcreNTk5ZWztae9onTpg3,Temozolomide capsule; Testosterone Cypionate; Vinblastin; carboplatin; lomustine; temozolomide; triamcinolone; vinblastine; vincristine,9,136,1573
eanWIqDZkP.H1u1CHeBJdjyJPyQ6iMl0yUlhB5UP4V.o3,triamcinolone,1,1,0
earzwXCte9lV9d-Lg98oDiUidN6DpdTGM9G-8dV.626k3,Ketoconazole; Valproic Acid,2,3,469
easKVTWXVHV5mKFllffBnbnConlonvSHN-pvFgy66z.o3,Cyclophosphamid; Cyclophosphamide; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; vincristine,11,98,88
eavVyFVyENJmwouvdhgWuxna7-CF-SVnAx95a.qJpaa03,etoposide,1,5,21
eayMXBGjmbBfzMmE5tGev.7Ioso2t085bE1vG3tcBhJE3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Neulasta; Temozolomide capsule; Valproic Acid; carboplatin; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; methotrexate; pegfilgrastim; temozolomide; vincristine,21,292,480
eb32vNrjZA.Av0ni3XSgLjA3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Progesterone; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,11,105,3442
eb6OQd2Xz2WHfGOrABzUmCY0NO2yG2HmxykglaDvVP9s3,Progesterone; Temozolomide capsule; bevacizumab; lomustine; temozolomide,5,318,2898
eb9VQVIeBsvPD37XzTCFE4swnY90h2zrmIlt891oxuaU3,Tagrisso; osimertinib; osimertinib mesylate,3,5,77
ebDFTvhdy-DvBsDYAn-P.Qtveb4yALLr3w2Rwgoo-9-k3,triamcinolone,1,1,0
ebEObH4uPw.GDroXHsMbWz-XLls9m4Cb1oZ.ty5tSpyk3,Cyclophosphamid; Cyclophosphamide; G-CSF; Prexasertib; Temozolomide capsule; carboplatin; etoposide; filgrastim; mesna; temozolomide; vincristine,11,43,540
ebMAX9.nfOxGaiDng-vmQ0BZJnCK4SLg88qE-.NGL8Wo3,Vitrakvi; larotrectinib; triamcinolone,3,6,763
ebP2Bns96L3PYKOiVWruZ2w3,Zofran; bevacizumab; etoposide; lomustine,4,16,119
ebQT30sudKrF.x2m-y5.XTldd85G3UCv9mRxDrir603A3,propranolol; triamcinolone,2,12,201
ebUbI4HWneS7zKabMoXzWzHNDXBdF1iu6g2M8CkqF-KE3,cisplatin; lomustine; triamcinolone; vincristine,4,90,917
ebV4sLBixFINXVyH8So4RHHEoaDBPh82qS.SV19NQ5T03,Temozolomide capsule; bevacizumab; irinotecan; temozolomide; vorinostat,5,61,340
ebZ3SPSjo7jlpdG5I7Nq.Nw3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Pentoxifylline; Valproic Acid; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; temozolomide; topotecan; vincristine,18,445,2992
ebi7UFahPpDQ-qX.vY7G0OZPo8iw5jIK1ixf0GT-5fn03,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vorinostat",111,1016,742
ebjV51YrgvJRyu2B-yhiR3.9CX0Lw2wthyaLrYZWTAwc3,Investigational Chemotherapy (unspecified); Valproic Acid; Vincristine Sulfate; irinotecan; temozolomide; vincristine,6,99,580
ebo6v4Wz2XEnMDaudX9QR4j8WFn12iD5Mhd3bfe09bXc3,carboplatin; vincristine,2,118,314
ebuRP3pPWkcUSP9I.ZOscJBb3N-CABfJpVIWiVYxayYc3,Testosterone Cypionate,1,6,432
ebvImgPocBXOZrasDRAPq8w1EcnuitnqauzhKPp5uss43,Cyclophosphamid; Cyclophosphamide; G-CSF; cisplatin; filgrastim; lomustine; mesna; vincristine,8,128,399
ebvQ9rFL6eI89TM8MUaL.JOeSqvnYbXT4OLHRjHGdmNQ3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Lupron Depot; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; leuprolide; mesna; methotrexate; pegfilgrastim; temozolomide; vincristine,17,328,2741
ebvgzsE9LrbvAt5kEiajc6AYV1B2wKjlz1gZuh4mgowE3,Testosterone Cypionate,1,12,1506
ebwk2qY9jpSnhW1IFx22mvYjRYXK50LulvkIZgNi-Knc3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; methylnaltrexone; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; plerixafor; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",124,703,1049
ec-LXjB0OkRd6rcKUShRPjg3,ATRA; Temozolomide capsule; irinotecan; letrozole; propranolol; temozolomide,6,25,4356
ec.F4S8FgK40crIqyswhfQ0yXmTeJ0tWmu5zb5jy7ZUc3,Vinblastin; bevacizumab; carboplatin; triamcinolone; vinblastine; vincristine,6,85,1080
ec2eGZuioEeu9n0IvFCg-Hvy4yO6P2VDI4M9YsuKlmfA3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; irinotecan; lomustine; mesna; pegfilgrastim; temozolomide; vincristine,14,276,1913
ecGOf6-CL338Dai1hNn5HNV6oM7nv4pqJSWlT3hJLoto3,Cyclophosphamid; Cyclophosphamide; dactinomycin; etoposide; filgrastim; mesna; pegfilgrastim; vincristine,8,235,1514
ecGXakb.Ofv2-u6iR.S-4wBCU.sS4Lmab88Rl03T0Llk3,Dabrafenib Mesylate; Ketoconazole; Lupron Depot; Mekinist; Tafinlar; bevacizumab; dabrafenib; leuprolide; leuprolide acetate; trametinib,10,61,1947
ecKghinUQVl9Q6cMoA0RD1qZHVzp7JHW12RpiW1UMx0A3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Neulasta; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; vincristine,14,134,171
ecLBolM1Hew6-2Wj--3qGp4KOLkqDdRyBOru43u5FZ.M3,Investigational Chemotherapy (unspecified); Mekinist; Zelboraf; trametinib; triamcinolone; vemurafenib,6,27,354
ecRO7TrYsDA43sn0Sp0r6PAArR.vhMq6RFDiV96zIys83,Temodar; Temozolomide capsule; Valproic Acid; bevacizumab; etoposide; irinotecan; temozolomide,7,121,657
ecVjQegye..e2Ncd6HbnS3Q3,carboplatin; vincristine,2,50,111
ecXR0N3Ij.KYWyYl.IbrLIc2QvGervzkdfUueE3nF9ao3,tretinoin,1,1,0
ecYIj400QuvSrSZLLSN3QmMM7U-gdOEfIuX3JiAacGXM3,Temozolomide capsule; bevacizumab; irinotecan; temozolomide,4,139,484
ecZ6jYf9F1c7kQsWl-Uxukg3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Testosterone Cypionate; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",111,129,1953
ecZjPnIv-Q4pzQWhgOjZOVyixlM7RtHxN8bnbTXjczt03,Ketoconazole; Vinblastin; bevacizumab; carboplatin; rasburicase; vinblastine; vincristine,7,369,795
eckxo-nXwlFFoteb7LXFJcYc7kXpYqw5DroaD7.Z6HRg3,Cyclophosphamid; Cyclophosphamide; Cytoxan; Thalomid; bevacizumab; etoposide; thalidomide; topotecan,8,333,632
ecs4PkxrJTz02vtt6SLxiav4ScHek0ABfyELE26kwzS83,Investigational Chemotherapy (unspecified); Valproic Acid,2,14,1264
ecuOhnjtGGUhEQgPz2Bokh8GYFmt9RZZB6yi-8vLv6943,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Keytruda; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; Opdualag; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pembrolizumab; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",116,2568,1292
ecxNcw3xmWtjxD1z9UyMfNT4-iedtbInabMVij42edvk3,Testosterone Cypionate,1,13,1365
ecyvxIuPV7YUvZX6Tr1pxDn1zT7IiicYJdEXVnV6vJxI3,Cyclophosphamid; Cyclophosphamide; dactinomycin; filgrastim; mesna; pegfilgrastim; vincristine,7,183,210
ed083bsob87rkCQ9URpyrWdBx1R1DYthZeLo1lZhu37Y3,propranolol,1,3,0
ed0AwzLnVpXjGonTnnB456Q3,IMPACT; Vincristine Sulfate; Zofran; carboplatin; vincristine,5,61,3736
ed0lx0rHEnA3qvJa8.V.mtVE-x8v8.QMqchprXQiaZ9U3,Progesterone; Temozolomide capsule; bevacizumab; irinotecan; temozolomide,5,112,365
ed0mFyfSpZEF70M3oZJ-HCHMeLHmTEjXoArv6w.99aME3,carboplatin; etoposide; filgrastim; pegfilgrastim; vincristine,5,54,140
edAOixA4HxmVp2Y2GU5rQRdEjXfcTxDLUYpeNAPxM4E03,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Valproic Acid; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",113,337,142
edAbZLv8Lm4xLjiGarm3XJ.KP5mE-pSycoKnJSutR4-g3,Temodar; etoposide; isotretinoin; topotecan; tretinoin; triamcinolone,6,7,686
edDR091F1jqKfXFQeJdOkOcO0SrZyAmhz3PEX0E8TVdE3,Ketoconazole; cisplatin; isotretinoin; lomustine; tretinoin; vincristine,6,101,455
edHFHoGK759IKXqEHTDdjpDlUGDXPeaiHqQ-n2OtafS03,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; thiotepa; vincristine,13,120,128
edIQULlOaCVTvkg4EpVQ0Fe8gGHr-pj.MG49nqKBc26w3,ATRA; Cyclophosphamid; Cyclophosphamide; Fulphila; G-CSF; Glutamine; Temozolomide capsule; cabozantinib; cabozantinib s-malate; carboplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; gemcitabine; irinotecan; melphalan; paclitaxel; pegfilgrastim; plerixafor; temozolomide; topotecan; vincristine,24,202,918
edK9GyiFR-8pXoNBMnl30Ir-AIMdehMsOzHKH.qtsEj43,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; vincristine,10,87,72
edKF.pmEOX1il2wVzvlm8kw3,Pentoxifylline; Progesterone,2,5,146
edKPBngVd7zTAT1LHgMQAYVQXdfZzu7D06NGr7qh-4kE3,Cyclophosphamid; Cyclophosphamide; G-CSF; carboplatin; dexrazoxane; doxorubicin; etoposide; filgrastim,8,80,111
edLSWicqEUCjT.jqRLV0eJ3TX4.CuDNfRFXRktAozcEY3,Koselugo; carboplatin; selumetinib; triamcinolone; vincristine,5,19,563
edLUSSwUwIdMjOSK4kLrna1pJ7jpvkYq5DJ3t8GrLzis3,Blincyto; blinatumomab; methotrexate,3,117,435
edMzP3Uczl-OM75kTd8DryB1IArdXD0yyQxx9tJTsp5M3,Fulphila; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,31,68
edOAdmRvw-LioRTh3SKi-Pnb3oxH6ofE7-wuT4T4zEl03,Testosterone Cypionate,1,27,1266
edRPyBsaGmJR9jFr0Nk8rAYINhDgc.4EUNjW0jzUMeW43,G-CSF; Glutamine; Temozolomide capsule; carboplatin; etoposide; filgrastim; temozolomide; thiotepa,8,22,597
edYxkZ33idfWEqu2TvsfEWA3,carboplatin; vincristine,2,148,447
edgcWYjCR.P8U4gsfocuhwF-jPSNrUeHcjr42yKmT-L83,triamcinolone,1,1,0
edkYkzWCnNiiW5PmO2yDjo5rALFYQWd7sbf.KOI7B07o3,Vinblastin; bevacizumab; carboplatin; vinblastine; vincristine,5,452,1331
ednUbeWuvA5TGPbz4M.avvw3,Matulane; Tabloid; Vinblastin; lomustine; procarbazine; thioguanine; vinblastine; vincristine,8,237,959
ednvJ7XPe1kmpwqaKkO-M5N7c9.8Xe98mFVoZmXPwxQk3,triamcinolone,1,7,3187
edoJr.jY3bW2SB1BUF92MAcKwAq948Si1rz6n0wGMi-s3,Valproic Acid,1,3,11
edrDzbf2isHlj1AsNLY7W2ZY7pgouBcKnDwx9CnGhcwE3,Valproic Acid,1,53,78
ee.vDSw0gTPY8qQHdd80XmORJluiMcJon.akLbCu2QOo3,Cyclophosphamid; Cyclophosphamide; Leucovorin; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; irinotecan; methotrexate; pegfilgrastim; temozolomide; vincristine,15,217,226
eeJQrpfi87aa.HKM95hOCNjCRQFN5Uvj7f3VyHoBXDF43,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",113,1660,2249
eeQbCY-0CAYiOEjNNRmEgq-ySUOljim000gM653Yk1RY3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Valproic Acid; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",111,224,83
eeQgv8q5TPmBzRorTcI.M1DyXCfWkEOxD3b0HJpHPHd03,etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,5,10,5
eeUzQ.iS0QTPzEck9d82mtA3,Ketoconazole; tretinoin,2,4,173
eeXYYHEPQW-qNV6ArqwJF8xE.UsCLHZW.crmLy.LDono3,Progesterone,1,2,63
eeXjEKKpVX.cEv1JtJBJAdTy2KFvl9gzh21zFSh-RUQI3,Cyclophosphamid; Cyclophosphamide; cisplatin; lomustine; vincristine,5,98,393
eeZt0ljadf0tyjJJoVurXyg3,Valproic Acid,1,4,0
eeaqHWe1GLVzmSfBP6loKsgwCYcZEGFoBkypFgvEwZto3,Cyclophosphamid; Cyclophosphamide; Rituxan; mesna; rituximab; tocilizumab,6,31,128
eed6Zy5WX7aMXlDSXn2cN.Q3,Investigational Chemotherapy (unspecified); Ketoconazole; Koselugo; Lupron Depot; Progesterone; Valproic Acid; Vinblastin; Zofran; leuprolide; propranolol; selumetinib; sirolimus; triamcinolone; vinblastine,14,43,4795
eel.2scTD1TEIN38YEuJUE3uXusUhfMUdYSgmgrKQZsc3,vincristine,1,12,33
eepdshDlMv4t7CaxpKLTAw0fWLOGTTqmpXczAAiacu503,carboplatin; vincristine,2,48,328
eevjCBp.BbM2co0MQ8Krx5ThVzYqPyNyB9rFRUv5-K7g3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Acetic Acid; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",116,6041,2788
eeyNhyamy22HE7zyREI9Rlg3,Valproic Acid,1,2,0
efEidDmwQBGeWOTwuckgVXA3,Temozolomide capsule; Valproic Acid; bevacizumab; etoposide; irinotecan; temozolomide,6,263,1714
efF-MRP-bf-IChrignTSegHHw-b04jUjk.lwQz0jcH283,ATRA,1,1,0
efLjdFm.jOfImEOPpI.miwxrpJnmj-UVjnhiZNiD6N4Y3,Temozolomide capsule; bevacizumab; irinotecan; temozolomide,4,137,455
efa8y3QuzG4dOLAdWXadpo-s7d2QRdKQYgIDifbU3NtA3,ATRA; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,45,188
efaa2eBgbAYCksSc6f2Wzny2I0axppgzYu5hkMD4feac3,COPP; propranolol; tocilizumab; triamcinolone,4,10,404
efcACPnQ4rxylucDDJkoUHRvOdx5n-kPMkxx.R0TDKNw3,triamcinolone,1,1,0
effWARcP1du0rqxqna1OTSa8SmkJ7IoWhXAxLc780IkQ3,Cyclophosphamid; Cyclophosphamide; Thalomid; bevacizumab; etoposide; temozolomide; thalidomide; triamcinolone,8,122,2188
efi.SdqOv9HInFwb1PjLX1g3,Aranesp; Rituxan; Testosterone Cypionate; Valproic Acid; Zofran; bortezomib; epoetin alfa; rituximab,8,52,5220
efm5wVpZMr1ETjpUziiwOYY6dZy.UJm0oxsoiXRlc2Es3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; Valproic Acid; cisplatin; filgrastim; gemcitabine; mesna; pegfilgrastim; pemetrexed; temozolomide; vincristine; zoledronic acid,13,136,634
efrD4bgU9FMvdxVXPukNZlIrE8C7Tet4u6Bl2O6o2oZc3,Mekinist; carboplatin; trametinib; vincristine,4,166,1421
efrgGHzxi6VbW.aUMBMcvWTbDRGjikyz7URNrTyMfGEE3,Progesterone; dexrazoxane; doxorubicin; mercaptopurine; methotrexate; vincristine,6,132,352
efxIdlMMM5loOTNxD4bbvU8xLTVyl55ipbmIrdwwMKuQ3,Cyclophosphamid; Cyclophosphamide; Fludara; G-CSF; Rituxan; Vinorelbine; busulfan; clofarabine; cytarabine; defibrotide; filgrastim; fludarabine; gemtuzumab ozogamicin; mesna; rituximab; thiotepa; topotecan,17,60,185
eg2PMo9ni2ujSd0zlO6qPyTknt3hQ5wmlqrcCZDglvH83,Valproic Acid; propranolol,2,3,159
eg75PyTaVapGVhDO0Cn.6F3KlHeVtMD6CJLkT20sA7u03,Ketoconazole,1,1,0
egDhAedVitSx3Xdkvx.GNJJPJpnD6a734pUXAE.hq4eQ3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Temozolomide capsule; Valproic Acid; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; temozolomide; triamcinolone; vincristine,18,334,1928
egEpcL1RpVQSajpGGItzDgQ3,triamcinolone,1,1,0
egF21IxGiYdPqGLfP.h4gtrXOEs3kuu3dKtcetQXEnHQ3,ATRA; Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Leucovorin; Nivestym; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; triamcinolone; vincristine,18,110,198
egKK5j9m5.qTybhL2jPnuE0HavmMyguexShd0wzGXrY83,Cyclophosphamid; Cyclophosphamide; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,8,48,101
egMLqtKB3ahYME29jDG1q6ZiIoXsbzPtuY8zwkP7NU303,ATRA; carboplatin; vincristine,3,153,462
egOKPhv5eZYODQsmV4FHCmJe4FsK9Pd7A2DWlhjL0NdA3,Cyclophosphamid; Cyclophosphamide; G-CSF; filgrastim; pegfilgrastim; topotecan,6,18,4
ega5PUpYio84yt2HJblUscu0rNl3H7qpHNUyiFdVfl3o3,carboplatin; vincristine,2,30,62
egchq49h7432XwUmO-vufGAULr6eyNPri6DE0l-i39Hk3,Cyclophosphamid; Cyclophosphamide; Leucovorin; cisplatin; cytarabine; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; vincristine,12,82,51
egg3VO0dxHG5YpuZyzm7u4jVCnWZ1ymuGRqdgJBR1iaA3,azacitidine; carboplatin; etoposide; temozolomide,4,59,420
egqAY1l48nR2GsN-qJ4COItJC3vBipxNR-ox30Sp6gEk3,Dabrafenib Mesylate; Mekinist; Tafinlar; bevacizumab; carboplatin; dabrafenib; trametinib; vincristine,8,123,985
egrK2lSfBq3VVCBeu4P3vosRBSf7jjmWkZS8eajcOJrw3,clofarabine,1,4,26
egrNzeqpKdS5LX0lwemkKNQ3,Acetic Acid; Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Testosterone Cypionate; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,12,110,3642
egtJrN3CEvzqFWDslTkmjfA3,Abatacept; Aldara; Hizentra; Infliximab; propranolol; sirolimus,6,26,4080
eguCFHGIZl6JNbmvv5lN27KwPE0hODT3PL83Fx-uC46E3,Temozolomide capsule; Valproic Acid; temozolomide,3,14,105
eh2AZqgdl7jqx7IU2GEfxutoXxRlJGveQrxNOv1P0yAk3,triamcinolone,1,1,0
eh8Geguc4Pxhv7Rautaai.3.9CEADVG9jklu-GQjS1sw3,Dabrafenib Mesylate; Mekinist; Progesterone; Tafinlar; dabrafenib; trametinib,6,64,1080
eh9kF18FPelyunOdfVC-8pdIy.MfLfjfLVW000Dg5vLI3,Cyclophosphamid; Cyclophosphamide; carboplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; pegfilgrastim; topotecan,9,142,197
ehNHy6rHJWWZZfYSy0pSqWw3,Temozolomide capsule; bevacizumab; nivolumab; temozolomide,4,131,791
ehTIyzNPewiN4eKBuEMpbtoMD17QYrnXch09F.h-1R7w3,Pentoxifylline; Zofran,2,24,1933
ehWTJAfqyNKYpfGOBDtesQXjyMlyVUs6dclG-aTnLeRU3,Temozolomide capsule; Valproic Acid; bevacizumab; lomustine; temozolomide,5,32,324
ehWYEqPAopG1YERkd47hZWwIx-kpnDwOM5EBKHpDRFUM3,bevacizumab; carboplatin; vincristine,3,216,2147
ehdU2bHUcJJXf2LdvzLF22dPRF.1Kzr3buXmo1W.J9pQ3,Afinitor; triamcinolone,2,3,334
ehdWyH4mwiOU.4rQs3ok.MUz7-Bp0L.Ax2hxSZvKwzcU3,Progesterone,1,2,650
ehhcjaHV26UI5j2UzWTNKVGrbbo15oMBapPNn8-iHGAM3,ATRA; Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; GM-CSF; Glutamine; Neulasta; carboplatin; cisplatin; defibrotide; dexrazoxane; dinutuximab; doxorubicin; etoposide; etoposide phosphate; filgrastim; isotretinoin; melphalan; mesna; pegfilgrastim; plerixafor; thiotepa; topotecan; tretinoin; vincristine,26,174,578
ehiHcXfbnfv1Rc9iiRzJ.VW78nboA6G.-lOoE6uXSIiM3,IMPACT; Testosterone Cypionate; Valproic Acid; zoledronic acid,4,14,749
ehlIYRggqww8jEKIjJmxSAQ3,cabergoline,1,12,1472
ehlcE.vqz1gkXfZe4B7mmJ.G0UeYCGlzoYaBf94ogNzw3,triamcinolone,1,1,0
ehtCYfy8XFQGdACGmcqgZQ9cSzFLDIwbK.whNw1J.rbU3,Cyclophosphamid; Cyclophosphamide; Neulasta; Vinorelbine; dactinomycin; dexrazoxane; doxorubicin; filgrastim; ifosfamide; irinotecan; mesna; pegfilgrastim; sirolimus; temsirolimus; triamcinolone; vincristine,16,281,499
ehx0Zyfj3bwy3mJKJaLNTfmbDz3Kw4AvVeW7Dapa7b7Q3,Resveratrol; Valproic Acid; everolimus,3,5,6
ei.tLgPfPx6nnyopgLggiZLYpxh3IcHy.zQOEaPwcX2Y3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; acetylcysteine; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; propranolol; thiotepa; vincristine,17,107,189
ei1R-kmAbm2P4fwQjilvYu54rUIY98Uh9T4fEHAySUwI3,Cyclophosphamid; Cyclophosphamide; Neulasta; bevacizumab; cisplatin; filgrastim; gemcitabine; mesna; pegfilgrastim; pemetrexed; vincristine,11,102,216
ei440LtOiErYPTCxCYIYYA3TRDfAprVnoxYAic2FOQ6o3,Cyclophosphamid; Cyclophosphamide; Daunorubicin; Progesterone; busulfan; cytarabine; dexrazoxane; etoposide; mesna,9,47,2806
ei4FsRQawF6QI6tgifauaaQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Pentoxifylline; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; Revlimid; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Tabloid; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; erdafitinib; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lenalidomide; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thioguanine; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",122,654,2471
ei690OeHHxCVCmZcMXD0wSQ3,Testosterone Cypionate; Vinblastin; bevacizumab; carboplatin; lomustine; procarbazine; thioguanine; trametinib; vinblastine; vincristine,10,360,4425
eiDp2cgB8yFqn0ksYWIUI-ZNR333iyDcpyg5XXo7N3SM3,Acetic Acid; G-CSF; Glutamine; carboplatin; filgrastim; sirolimus; thiotepa; tretinoin; vincristine,9,43,5233
eiEBsyexi3f1KtEkMrBYFM-RUKmZvF-oUx.XJdxRNKyI3,Testosterone Cypionate; Testosterone Gel,2,21,2046
eiId0LTrKqraUJ4ku2iYeWA9IkPygDOpOV0bbeIqxti03,Temozolomide capsule; everolimus; lomustine; temozolomide,4,20,218
eiJwDg5eQsocOq8Wt-3BQBA3,Temozolomide capsule; temozolomide,2,20,562
eiPJfFjY4PRxbfixc9ilowjxehvgWI9u2O6wFEyJSr4k3,Testosterone Cypionate,1,5,528
eiS.rMFpyWe7sCWBSJC7LXwEYmsNF4uW7srrhLnduepA3,carboplatin; vincristine,2,72,335
eiT7a.lGtHc.eXoHIa1rnAwm0Upe11FGJNgAums8WH0s3,Cyclophosphamid; Cyclophosphamide; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; vincristine,8,80,77
eiUGy3hwCOEyf7VfL99Ib4svINKl3NEB9fux7L2EuaLU3,ATRA,1,1,0
eiUsqgxzv3G-iyVkIxKiGjKTvHcoeuODCN0KiFew-wxc3,lomustine; procarbazine; thioguanine,3,15,142
eiY6Jgw4Ugbv5FOe5aFmEFmHYHA7qPsTNu0dCqP7dgZI3,Investigational Chemotherapy (unspecified); Lupron Depot; Temozolomide capsule; bevacizumab; irinotecan; leuprolide; temozolomide; vorinostat,8,17,174
eiZ8gIQ.xVzYybDaR2sW5E0z9yI5BQjDeWulBFer5T4g3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,456,91
eiaOb2fr5LvRGNwWTGSjezQ3,ATRA; Progesterone; Temozolomide capsule; bevacizumab; irinotecan; temozolomide,6,11,217
eibLrkae3hLW.63yK.bsFplqBbNwihOB.YO3EV-lh5nM3,triamcinolone,1,2,0
eibuhdW6U0KlQekxUsXfpp6g4OGDYgqi2zi3iVXalYIA3,carboplatin; vincristine,2,190,1750
eicOekFaGLo-xKH07Du.CfA3,Temozolomide capsule; bevacizumab; irinotecan; temozolomide,4,20,28
eilLm.3aL8rZpQZc6eD0jmjxs-is3fnnGdOkBi91aBJI3,carboplatin; etoposide,2,16,70
eilPhnigRJiIcQlkZjJFeNZojI6Fd1TPgEjXFKxjUnXk3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; Glutamine; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thiotepa; trametinib; trametinib dimethyl sulfoxide; tretinoin; two-drug chemotherapy group; vincristine; vorinostat",125,2302,619
eioxjauEHTht0sbC.ONJA0kc4EkvpZ3T.hsZ-r9X6Lzo3,Cyclophosphamid; Cyclophosphamide; Neulasta; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,9,100,98
eix8FBE5aGyFMPu87rRVDPW9benYD1jXedKp754XbQQg3,Progesterone,1,1,0
ej.fSF9bwsmSIosATwMGXyg0VPsifwm2tCNemmJmxsws3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Neupogen; Nivestym; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; vincristine,17,109,129
ej7Vt7TDS30gL6pdz1CxDiQnxavdJbujKxBC6g69r4pM3,Neulasta; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,80,134
ej8ANP03ZNfR1vDlWsDqnDw3,Testosterone Cypionate,1,7,1016
ejFS5LwQoHk1otHPVFkd59g3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; acetylcysteine; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",113,120,4856
ejH1mxDZM8UM03r4BNKhcpC5VgmFvAV-7fbyWF4nQ5xA3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Leucovorin; cisplatin; etoposide; filgrastim; mesna; methotrexate; propranolol; vincristine,12,83,56
ejILk1GUk3qvCeZyGyZdxW7FWBWdaV2VO.Bbak1qV5ew3,carboplatin; vincristine,2,523,407
ejOIwwvXtAi4St7aC.0NEvOQnXj9iDRqQhVMAwoTacII3,carboplatin; vincristine,2,54,149
ejP0IoU2QrEgmtmWz0u6qGokDunvFztBq0fccREbrzFI3,Neupogen,1,1,0
ejPpSl6cFPs7eRSUyYKokUNLua5mXlLXQHvXPv0OiIVk3,Cyclophosphamid; Cyclophosphamide; G-CSF; Valproic Acid; anastrozole; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,11,87,1332
ejQRrpj.OHF.0d1xv-g21jKZKuGGXgpBi2LiblaJDBt03,temozolomide,1,5,14
ejSf3jwd-BpxaWcCdPtqHl09ILbufZNEd7hFa3FSkB6A3,carboplatin; leuprolide; leuprolide acetate; vincristine,4,106,273
ejTMYY4pYxRXjUVVyueZGNaFrRqYZB0WR.tCUL0jFHxA3,carboplatin; etoposide; filgrastim; pegfilgrastim,4,24,47
ejbv7pcmmd6oAhkKIvs.UTzRh43uiNSi1hZMtP89PLNs3,temozolomide,1,9,18
ejeRY6zT2iTLz7RiOuzDsEeq0RAL-2yX7QV8YQ.lyThg3,Dabrafenib Mesylate; dabrafenib; trametinib,3,30,246
ejjhdzKsQnLdKP0l-sdj7CwAYhIvDi8CO6SGBOO7Ze4U3,triamcinolone,1,2,7
ejvDUOufn1btmvwmwmwwRlOuQa-kaY7o3uiMCYsGtIbA3,cabergoline,1,3,54
ejvneiNQ.pjNDp.JSKGaxIrL-6rw9Ga.GKkfDbg-Jac43,Ketoconazole; Oxytocin; Testosterone Cypionate; Valproic Acid; triamcinolone,5,11,2615
ejwIifXrGmOTKFcmGBp4UayeKEguve66QOiFGNM5K.K43,Caphosol; Cyclophosphamid; Cyclophosphamide; Investigational Chemotherapy (unspecified); Progesterone; Temozolomide capsule; cabozantinib; cabozantinib s-malate; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; irinotecan; mesna; pegfilgrastim; pembrolizumab; regorafenib; temozolomide; topotecan; trabectedin; vincristine,22,282,2178
ek-mYQzidvn66-FkBNqv-okotU1F57Nf9IVL2gu-96.I3,carboplatin; vincristine,2,134,381
ek.A7KhFJBRBDWeordWinNg3,Cyclophosphamid; Cyclophosphamide; lomustine; mesna; procarbazine; thioguanine; vincristine,7,73,402
ek.TLtPyaitP2AUpmYWOr1Q3,Testosterone Cypionate; triamcinolone,2,52,3583
ek25k2KnKC2i0QQUEWqQNdA3,Temozolomide capsule; temozolomide,2,15,268
ek92FgoIdKiZAVlLMSt6Rlw3,Cyclophosphamid; Cyclophosphamide; G-CSF; Temozolomide capsule; amifostine; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; temozolomide; vincristine,13,132,549
ekGWWd2kKgXmEw7Ek0o1z2gBs4QBTTK4ZPvXbKYZySkY3,Adalimumab,1,2,9
ekOgETpDBGDSCkWWR-mKaBgC04u.QvhEceNhuBuLedL43,Ketoconazole,1,1,0
ekWGDrbYVj415IZB0zNtrZc9Peqax-zC3OlQoHpwrdDM3,Testosterone Cypionate,1,16,962
ekdVijY64GxFKOxsk.EcD0yc-KivpdwyblxDAi92L.fI3,Valproic Acid; carboplatin; vincristine,3,157,602
ekhVIdpjt3XxH4tVYc-d5xv-e3GJIMKWRXZvNv1mve703,ATRA; Cyclophosphamid; Cyclophosphamide; Fulphila; G-CSF; GM-CSF; Glutamine; Leucovorin; Nivestym; Ziextenzo; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; irinotecan; mesna; methotrexate; pegfilgrastim; temozolomide; thiotepa; topotecan; vincristine,23,228,1089
ekjvQ-Ty-g0yFbVU1e6T41pwHju9DSS080mjJB0tmhKw3,Zofran; triamcinolone,2,2,0
eklx1nKW2stTTulOYULMBuWX8mFi9s2WLqqYJsytQZt03,Chemotherapy; Cyclophosphamid; Cyclophosphamide; Cytoxan; Emend; Temodar; Temozolomide capsule; Thalomid; arsenic trioxide; bevacizumab; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; hydroxyurea; methotrexate; pegfilgrastim; temozolomide; thalidomide; topotecan; tretinoin; triamcinolone; vincristine,26,833,2067
ekrJf9m27ER1umcVah.rRqC.9hDY9ch91PfbuGjUHko03,Temozolomide capsule; lomustine; temozolomide,3,6,12
ekrwBvetBzwC2P5rxAqFfXZzslqMQrS7oha3umEU6gF83,triamcinolone,1,1,0
elAlyoIpFTWEOnWcwxf-yoSoIYVL6AoakUls0z706Z3g3,Cyclophosphamid; Cyclophosphamide; amifostine; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,74,114
elJEU6dJzklwLOT.7TbHib.Z9i7ubn3NhlLsMUoPrQ843,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; vincristine,15,161,173
elK4deI1HFXEZjW4a1TnUexgwazEAHkHk39edlrmIH8c3,Acetic Acid; COPP; Cyclophosphamid; Cyclophosphamide; Leucovorin; acetylcysteine; mesna,7,22,3487
elSp4zCUFAH05JCvWPCCDM0Z8zMwmQF6kckdncGaLhzA3,Temozolomide capsule; bevacizumab; nivolumab; temozolomide,4,36,242
elTTbIEw5REpXeMDOv45uYJUFHGw9S-5SiGKPcjG0bbA3,ATRA,1,1,0
elU55NqsFeebaIMNrvf5CXQ2n1HAd7Qm.wounQOH0qBY3,Chloroquine; Dabrafenib Mesylate; Mekinist; Tafinlar; Temozolomide capsule; bevacizumab; dabrafenib; lomustine; temozolomide; trametinib; triamcinolone; vemurafenib,12,67,642
elf5HtNd4e90vd8JYu7QdWOHgh3e9PUrgZbg8XFvr-EU3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vinblastine; vorinostat",115,460,532
elfUaCzlo9mK4TXEQaytbng3,L-carnitine; Progesterone; triamcinolone,3,4,1
elglD6pWvd.XZdFARcesBvxGegOhgFWwFNiOReNo-Tsk3,Cyclophosphamid; Cyclophosphamide; Neulasta; Octreotide; Progesterone; Temozolomide capsule; dexrazoxane; docetaxel; doxorubicin; etoposide; filgrastim; gemcitabine; ifosfamide; irinotecan; mesna; pazopanib; pegfilgrastim; pembrolizumab; regorafenib; sirolimus; temozolomide; topotecan; trabectedin; vincristine,24,503,1771
elvq7S3m1939KQIigpHxvoJdF1TL7VS2BvKAwq9RjMos3,dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,142,234
elxNleLVxIZYTUTucDnlLxw3,IMPACT; sirolimus; triamcinolone,3,10,1645
elxbnne85ZyjQ.JeVNJMIdFunUOvfqEPGIYj4Nf9DXvA3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; tretinoin; vincristine,14,127,328
em08-CvfKeU6lkABOwnqsYYIdFPEeGCQf2ofs83dZE683,carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,6,64,111
em8qTmlFN0qhopOrPEPP-rWrA9XoWV9n0W2bXlJ6nnfs3,carboplatin; vincristine,2,146,410
em9t4GgsjHTs4FH9TR8lUVkExZGYYGBHON52QbLb-aCM3,carboplatin; etoposide,2,12,21
emEZgnxDSxFRniG1ZsbxIK5cmXGqf3h5b8c-8SWo0JeU3,Leucovorin,1,1,0
emNJyEAZ2-DL6JFc01bvuhg3,Cyclophosphamid; Cyclophosphamide; G-CSF; Progesterone; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,11,89,482
emYd2hZO79qekX2AT6A5hdFiEThedgN5sxEDe8Do-gRg3,Progesterone; lomustine; procarbazine; thioguanine; vincristine,5,55,329
emahi6N4SJC0oRZciBI9zGQ3,Cabometyx; Investigational Chemotherapy (unspecified); Ketoconazole; Temozolomide capsule; Zofran; bevacizumab; cabozantinib; cabozantinib s-malate; lomustine; temozolomide; trametinib; tretinoin; triamcinolone,13,94,2223
emj8NQUawo3i2nGc8ZPulPsG3Tp3JzOxwRTI4uHIs6B03,triamcinolone,1,1,0
emphX.5r0Y1q7tXrhIZezdg3,Ketoconazole; Lipiodol; everolimus; sirolimus; tretinoin,5,14,2386
emyObQrM-z8pczz8n9AslxxfGbN6yQhNRgZqMbMXAjjs3,Acetic Acid; Cyclophosphamid; Cyclophosphamide; Cytoxan; Emend; Etopophos; G-CSF; GM-CSF; Glutamine; Leucovorin; Rylaze; Tazverik; asparaginase; bortezomib; carboplatin; cisplatin; cytarabine; dactinomycin; defibrotide; dexrazoxane; doxorubicin; etoposide; etoposide phosphate; filgrastim; isotretinoin; mercaptopurine; methotrexate; pegaspargase; pegfilgrastim; tazemetostat; temozolomide; thioguanine; thiotepa; topotecan; tretinoin; triamcinolone; vincristine,37,754,2133
en-zfT5hmI3nACs2jvfHwvMhi6WwnzoGIR5ogiSOqBtw3,Sufentanil,1,1,0
en9KoODIpEy4m3Ct3Bb16Myml2UNn6rSCggcyfaWFMGg3,etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,5,71,164
enBKg6QMnu4U64JZ1fRxGQlBcsd7kPtdqKnQm6itP4vY3,triamcinolone,1,1,0
enCJ7aAqCuj-B2GqpCFPQwvlEW6.3CDo4dviUr.Tx-Hk3,etoposide,1,6,25
enDBtW8mnOM2nmBkEWjh-fn9-WtvvtNRWT7zEsfdtj-Y3,propranolol,1,2,1686
enEsbDn9IQWZTI0tNYd-D7rvlsDqMk8.SJ0k-eAFbCF43,Temozolomide capsule; lomustine; temozolomide,3,46,340
enFVSU80NGQK4dQQI-9hOHzMTLCyk39Gr1h14fkCCu2I3,Cyclophosphamid; Cyclophosphamide; Ziextenzo; dactinomycin; filgrastim; mesna; pegfilgrastim; vincristine,8,185,286
enJm.EcnLmjNMn5xfhSR3p7RSchYJJbkfIN4Jkn5J.ks3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",109,344,108
enKpfIwaqn5wS3APnN45FGQ3,IMPACT; Investigational Chemotherapy (unspecified); selumetinib,3,11,90
enTx0pcvYZqqMSJpqC3b5MzMGp5DJ9EmDwAH6VcWNy5E3,carboplatin; etoposide,2,18,83
endZhtDaYAKIXMYw50yQk8rbUnT6OSrUKDcU72LhZ8xQ3,Neulasta; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,7,55,123
enen8-RpIWkLodbVcZHGc4Gt2.iQxz6uAOLVmZkNWMTo3,Temozolomide capsule; bevacizumab; temozolomide,3,22,29
enlT9U-OjasPT5q-aRmta7YseHWUBcc4r6HuRP2HDmks3,IMPACT; Octreotide; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,8,73,980
ennxsqGkRx4dt3ctzfejzST99f5ROz5gIx-6-cmpkdko3,ATRA,1,1,0
enrz8cxBfNpi9fz5HL4QEsd2QDBN2LleZu-YZTnzTtOI3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,450,70
enwPjzqY1YO7S8nsqNsdEcw3,Lupron Depot; leuprolide; triamcinolone,3,67,1973
eo4vhyiw9RdYemcdiam5LQImhz3vfME30zHu3.Ao.n583,Temozolomide capsule; bevacizumab; lomustine; procarbazine; temozolomide; thioguanine,6,81,540
eoA0IUD9yNPeuxPPiUouATJ9GJXsLuc.V.jCILPjXR9I3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",111,1242,1312
eoBVJESCiHvC4mqed0Hh6NIvOffvzx4QOqRw5R9MtJRI3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Zarxio; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; triamcinolone; vincristine,18,133,171
eoCf3jD9hgA4l5ceNtMyY3aUhR4sChKU7c.HtRwwMWic3,Investigational Chemotherapy (unspecified); pazopanib,2,3,0
eoDNSnKlnej5Uw-tYBxQXeEy3hZSdmEu7kKFCZgxeGVk3,Testosterone Cypionate,1,1,0
eoJb-p3.PhnrnOdg7huSUzyc509NXx03.C6bfeOkm5.M3,Cyclophosphamid; Cyclophosphamide; Eculizumab; Fulphila; G-CSF; GM-CSF; Glutamine; bevacizumab; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; vincristine,16,124,402
eoMuH0PdcvRYicCPkeNj.qoqXRAY0iBWySfWd1hOJ6QA3,carboplatin,1,1,0
eoTM4616IVDBjR4sxDCccm2tNwnQJPCsj.x2oXqR.ffs3,carboplatin; vincristine,2,145,518
eoVs-0nWFssQpnU4Nf42X.925jCgQnbGeVNtpP7Z7PmY3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,329,37
eoWVJ3I9aZNlD92UaxuYdVg3,Progesterone; Valproic Acid,2,11,3037
eob1U-cg3FBJDM7TGlRFmGR7ZPNDmPDntdhzSjYLJU-Q3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; vincristine,13,123,166
eoj8GDpt3D55s3aHAQUkZVh51x6q44k5SK7xkcjrgD6Q3,Sufentanil,1,1,0
eomexm5Cy3TWeTIJX56PX0ylr7bJbLD-I.bCoYLS5Tnk3,Koselugo; Temozolomide capsule; Vinblastin; bevacizumab; carboplatin; everolimus; irinotecan; lomustine; procarbazine; selumetinib; temozolomide; thioguanine; triamcinolone; vinblastine; vincristine,15,511,4706
eou66qxL4As6BZ6e6Eymb0Q3,Testosterone Cypionate,1,19,2485
ep943kBhCNGRkJ0ytWisbMiqDc2CLBo4BSDKTNfAtUfk3,Tadalafil; bevacizumab; carboplatin; irinotecan; lomustine; procarbazine; thioguanine; vincristine,8,280,4984
epNSMyyPs7BwirEDsMRvfCQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; amifostine; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",119,1531,465
epOy0nmqhK.huZLrVI8JthQ3,triamcinolone,1,3,1750
epPonzCOwZNdThnYxtTuUzpmd9VV701QVMU5QPDIrNG43,Testosterone Cypionate,1,11,978
epQdM0NeM-wdIbtcbVku-0FnMm0wXcGT0sOHDqIWHNPk3,Avastin; Lupron Depot; Vinblastin; Vinblastine Sulfate; Vincristine Sulfate; Zofran; bevacizumab; irinotecan; leuprolide; leuprolide acetate; lomustine; procarbazine; thioguanine; triamcinolone; vinblastine; vincristine,16,342,2653
epR60Apkl2QulO5xJZ13sRg3,Dabrafenib Mesylate; Investigational Chemotherapy (unspecified); Ketoconazole; Temozolomide capsule; bevacizumab; dabrafenib; everolimus; nivolumab; temozolomide; trametinib; vemurafenib,11,63,322
epcSz0IBnXINLKmtGRgmIrA3,Temozolomide capsule; bevacizumab; temozolomide,3,41,179
epgx44Qa4kWsWdcj6-lVsIzcl2Ua4b12AC.uwQYX4HyU3,Cyclophosphamid; Cyclophosphamide; Daunorubicin; G-CSF; asparaginase; cytarabine; filgrastim; mercaptopurine; methotrexate; nelarabine; pegaspargase; vincristine,12,91,140
epiJc4G4isXMmlpXHYkLqakwWLgLHQZdPJWP2anNjiTE3,IMPACT; Investigational Chemotherapy (unspecified); Leucovorin; Valproic Acid; cisplatin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; methylnaltrexone; pegfilgrastim; triamcinolone,13,137,788
epktTR0ukfZQ3DOXis.Dmfg9qKnBsKddg7PjMN9y6O6E3,carboplatin; leuprolide; vincristine,3,151,419
epmqCmToQkb6UdG7pSB9ud97jOu38ZhS-i7lZ2YDQNWk3,tretinoin,1,1,0
epnL3fnj-vSFiGU1-90Iyne-j5D.FrPjJ9eN4yuPQJ3Y3,Cyclophosphamid; Cyclophosphamide; bevacizumab; etoposide; thalidomide; topotecan; triamcinolone,7,123,995
eppkHcJn8ErcqSclo3sKZpUjWsk1zuIW376VCnRjpGGU3,Cyclophosphamid; Cyclophosphamide; Ziextenzo; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,70,122
epsGP8GTrs31dDZsojk9qVvjnNp4Wm2VtZoPZmdBSfeo3,Ketoconazole; carboplatin; vincristine,3,153,1708
epuYDKU31O3qVDM5ubFFlMx2z2nAZ1Z8BiDgW-jU3XKQ3,Cyclophosphamid; Cyclophosphamide; Neulasta; Temozolomide capsule; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; triamcinolone; vincristine,16,312,2890
epvUEmVbm23e0k5Yfbis6bg3,Pentoxifylline; Testosterone Cypionate,2,4,440
eq0oylFT6ZuLW7LuXeCHq02UcCRJvk3bg-ajoRmn9YCU3,Cyclophosphamid; Cyclophosphamide; G-CSF; Temozolomide capsule; bevacizumab; cisplatin; filgrastim; irinotecan; mesna; pegfilgrastim; plerixafor; temozolomide; vincristine,13,177,1171
eqB7kn-z.OsSXHHPJSlRV1FxaWXhaAgHU-cKDLYMBoAY3,tretinoin,1,1,0
eqCVheu36VOcrer23yQt-Wb00thRPul4KaBasS9wes8k3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; amifostine; bevacizumab; cisplatin; etoposide; filgrastim; gemcitabine; irinotecan; mesna; pegfilgrastim; pemetrexed; temozolomide; vincristine,15,208,1029
eqIhcdbm4eBM-1TMOAuhqG5CiL0kAxpZp4XOervypIkY3,Valproic Acid,1,1,0
eqIncszlOf4vBUudqdzIzLnlcoJiGO7Frio1B5mfSxOI3,triamcinolone,1,1,0
eqJeZ2e8CnKFCGUvoAqyZQ-nlxXD9yLBMD1vsdkZOJ8M3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib Mesylate; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Tafinlar; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dabrafenib; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",115,1147,973
eqQ99EgI7OGYTPXMxAemsLT7DIKrJxWX47y7xG0caEwo3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,659,30
eqlFTGHziqtRTZqj5hNBCr0zRiZW9C4hKLxrYZvxhb0A3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",114,2124,2372
eqpbpU2T2Mh7i0p98jvIINWTULHf3YiSEZAHLdrwkC5g3,Cyclophosphamid; Cyclophosphamide; Eculizumab; Etopophos; G-CSF; GM-CSF; Glutamine; Neulasta; carboplatin; cisplatin; dexrazoxane; dinutuximab; doxorubicin; etoposide; etoposide phosphate; filgrastim; irinotecan; isotretinoin; melphalan; mesna; pegfilgrastim; temozolomide; thiotepa; topotecan; tretinoin; triamcinolone; vincristine,27,238,948
er-x-yQRU3uvAhiHkRv8Kxg3,Leucovorin; methotrexate; triamcinolone; vincristine,4,14,2068
er9Nra-snp32ovothVIlO5Q3,Pentoxifylline; Temodar; Temozolomide capsule; Valproic Acid; acetylcysteine; bevacizumab; etoposide; irinotecan; lomustine; propranolol; temozolomide; triamcinolone,12,216,873
erBsUbQCtNigu2xq3Pc3UmamO24j7FVU3v4iCP6HENgw3,Cyclophosphamid; Cyclophosphamide; cisplatin; dexrazoxane; doxorubicin; filgrastim; pegfilgrastim; vincristine,8,20,16
erIn3lB8pUBTI8tgYy8wxYg3,IMPACT; Progesterone,2,11,1750
erLAnzKr7UwPR33Ghs1fegPwLjM0ERIED.kDFz5Qjf0Q3,Valproic Acid,1,5,63
erMMzsbW5vTJ5DYTtDt0pZ.OqBH7awNQpem8JG24C5Z83,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Leucovorin; carboplatin; cisplatin; defibrotide; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,16,134,204
erOyAA3aEBvI.Z7e5cdPaNCryjdvSiQkaIoSiAEUuyx43,triamcinolone,1,1,0
erRA6W8SgfMsMnXOfIxQ7QA3,Progesterone; cisplatin; lomustine; triamcinolone; vincristine; zoledronic acid,6,108,4747
erSFnUToXre5azpwaT7WdiwmSCAdYpbXKw1W42hrpH-Y3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; vincristine,15,94,134
erUp-uTuqwaPFIQT.Qg6bAYkr5suY8.IYepsqeRzxlTc3,Ketoconazole; cisplatin; lomustine; tretinoin; vincristine,5,98,2008
erXsKAH0H-Jo3YzAFmLzUUZd7ztoq5034RJdNTsDJoaU3,carboplatin; etoposide,2,4,0
ereIqlIrXAAwoepFAG-f2qXEfuRumVbyEDV5R3qL9QPE3,Progesterone; Valproic Acid,2,9,1107
erfgC4mBlkVXFGvnjGbzetA3,IMPACT; Infliximab; triamcinolone,3,21,1259
ergSNVnqDHe80e1fkZyKrsA3,Ketoconazole; tretinoin; triamcinolone,3,4,1145
erhhICCRqq8dB5gjl0EG.Iz3ZgE32vhhO.5jMQgggDI43,Testosterone Cypionate; Vincristine Sulfate; Zofran; cisplatin; imiquimod; vincristine,6,15,1316
ermr0rjl9ufsNloe.9Wi.G.TpcJKOTtU5x6vpxIUKODc3,carboplatin; vincristine,2,136,398
eroBkBp3IJnl59BDXQ3IXuKtr5hLexQ6mgWF4JspCiE03,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; cisplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; mesna; pegfilgrastim; temozolomide; vincristine,13,159,202
ervYvgiZR0VWshEevDrJKEQNonmFCID.frXjk95KsqAc3,ATRA,1,2,1
erxhxDv.g.1mDoOn-MVrDjFfVFY1uRdjwcItN.kDglkM3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Valproic Acid; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; vincristine,11,85,136
es-QIUri6GZ9xVQuJptAlnVKN-F6Jg0DVeEd7i-J-htk3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Emend; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",115,685,113
es3G9YKRAlUAm3cxqjLsYP4xpEmDZMvtJqwh0zJpHtJI3,cisplatin; filgrastim; lomustine; pegfilgrastim; tretinoin; triamcinolone; vincristine,7,95,1436
es3gYZ9nVojbiu4SgoQtn6B3mDLAiHgWNUzTRAwXKnCw3,Progesterone,1,5,297
es5nMMBOkUXppvMuzs5hNHSKgU.SPVvGn0QAi2FzFcyk3,Temozolomide capsule; Testosterone Cypionate; Valproic Acid; Zofran; cisplatin; lomustine; temozolomide; tretinoin; vincristine,9,197,2846
es8sXctjURfswsBEXZM.B6AT4bsIaEbXgxisVtLgeNkE3,tretinoin,1,1,0
es9c-vcrW6EdB5t9edyqqRgGl24m-TkDp-WYT-eoYLqQ3,propranolol,1,9,211
esAhDsK6CnXqhzfbLs8DS8A3,Cyclophosphamid; Cyclophosphamide; G-CSF; amifostine; cisplatin; filgrastim; mesna; vincristine,8,90,119
esDZw6oOlw5ryg5egxiTL3x47aAJRmDv.ehpCZ0yPyCg3,Cyclophosphamid; Cyclophosphamide; Daunorubicin; G-CSF; IMPACT; Investigational Chemotherapy (unspecified); Progesterone; bortezomib; calaspargase pegol; calaspargase pegol-mknl; cytarabine; duvelisib; etoposide; filgrastim; mercaptopurine; methotrexate; pralatrexate; romidepsin; triamcinolone; vincristine,20,105,204
esHxnae2Zch3KsQezaJE5oe7XNGgPSM1F5cI6LAa.SQA3,Ketoconazole; cisplatin; imiquimod; lomustine; triamcinolone; vincristine,6,91,4492
esIrM2d71hwMJvyvG0ebiGADKfAEcyyU1qmDLk75r0VU3,tretinoin; triamcinolone,2,5,373
esJnYCGRlrAFNm2-gC5y.ad--Ug4ZyOJid2Zgrk1Djt83,Avastin; Cyclophosphamid; Cyclophosphamide; G-CSF; Investigational Chemotherapy (unspecified); Ketoconazole; Tazverik; Thalomid; bevacizumab; cytarabine; etoposide; filgrastim; tazemetostat; thalidomide; topotecan; triamcinolone,16,229,2072
esLxU8k4J0rDDelmkvzaiQw7vfYb2Q4GacvoCk8ajxDM3,bevacizumab; carboplatin; vincristine,3,100,285
esMb.evTf6r2YuiLXdphVuiVV45giZo5EPWYXtVzadA03,bevacizumab; irinotecan,2,154,728
esYEdTvAHvjZvg64rVPdPlQ3,Cyclophosphamid; Cyclophosphamide; cisplatin; etoposide; filgrastim; lomustine; pegfilgrastim; vincristine,8,96,363
escIibrHysHcDAH-1F0vbkw3,cisplatin; lomustine; vincristine,3,91,370
eshA75D1UjEhoxCHXdREN3Q3,Cyclophosphamid; Cyclophosphamide; cisplatin; lomustine; mesna; vincristine,6,102,377
esnNKnjpifmQhRcQYvHv4nw3,Cyclophosphamid; Cyclophosphamide; Octreotide; Temozolomide capsule; carboplatin; etoposide; filgrastim; irinotecan; pegfilgrastim; temozolomide; topotecan; vincristine,12,226,460
eswfLm0pWkho8oTvfKXzKjI.bcltFOliamLXoFcfmvEE3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Ojemda; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; tovorafenib; trametinib; trametinib dimethyl sulfoxide; tretinoin; triamcinolone; two-drug chemotherapy group; vorinostat",115,1231,691
et0EcFR38nvUPq0L.HFt8dmf5r11DoDnyI52YWGFViMI3,Ketoconazole; Valproic Acid,2,4,3666
et1saN9TRCzbqO6Rk1aZf9bRbsMbSGgu7vfgqd7IKrZg3,bevacizumab; carboplatin; irinotecan; triamcinolone; vincristine,5,114,4295
et6wfU.YVJULOPB5Kkt0117rChWRjheMaPOYwU-0pzSE3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Leucovorin; Ziextenzo; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; thiotepa; triamcinolone; vincristine,17,127,171
et6z.8NVA.2GSDBR9wIGugLGJoN3LItfHv6mIpUcvUNg3,Zofran,1,1,0
et7JBj4jWyMtFuamjLycLVGJT0UKEpvg02WVR3I5IaNM3,Acetic Acid; Cyclophosphamid; Cyclophosphamide; Investigational Chemotherapy (unspecified); amifostine; cisplatin; filgrastim; gemcitabine; letrozole; mesna; pegfilgrastim; pemetrexed; vincristine,13,133,2813
et7bjI-ApBNXtYbDsryiki8HTKUlfn61.tJ-NPwhtXQk3,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Leucovorin; Nivestym; Ziextenzo; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; plerixafor; thiotepa; vincristine,17,127,193
et8IF0xSI3.D2uXPovYCDtB-chFC7WbTcxV7Ho-qZFqw3,Mekinist; trametinib,2,14,678
etFeS.yLiScXab9Egrx9TSFmNT7OB7yAp-j2NILhhFcQ3,Ketoconazole; carboplatin; tretinoin; triamcinolone; vincristine,5,164,4627
etJVI9bmA4VCYaKAsdyFjyaqlw2w1q8deeshxtBG9i283,lomustine; procarbazine; thioguanine; vincristine,4,41,237
etKRYaO94xfd97rujHQH3KNF9HVo0FOHlAnm7HyOdBEk3,imiquimod,1,1,0
etQIzuP1B7OduILuUkL10SoL92tZ93qc6K7V8nP6xI203,bevacizumab,1,140,2562
etR-fT5qPV.-5i-W-rYxk5NRNTRWKQ3wAvLAJgvNQIK43,Valproic Acid,1,1,0
etUz6-yYpmPhHSjnlPC2BDA3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",113,1564,3517
etaoTFymXFDR3uO1W-R5k15MT8TpEstKrzP1CdJyLj.Q3,carboplatin; vincristine,2,12,12
etcF-LJ7ZRNuMzq1iqC4gsOaheQIlW3oxaLC-msyLHZY3,Cyclophosphamid; Cyclophosphamide; Ziextenzo; cisplatin; filgrastim; mesna; pegfilgrastim; vincristine,8,89,99
etnFwWDBwVSD0pmZawxaLJW3S2yJJySluXVZ0ydMVFFs3,Adalimumab; Infliximab; cabergoline; methotrexate,4,51,4918
etqBnMighpwbHshvVknXLIjt946NRZ8MTn-6eMPnNSnw3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Temozolomide capsule; bevacizumab; cisplatin; etoposide; filgrastim; lomustine; mercaptopurine; tbo-filgrastim; temozolomide; thioguanine; triamcinolone; vincristine,16,118,4296
ettxt0cMHgoH75JuPiyviNw1NMmDMVSQUFJ7At3wS0yI3,bevacizumab; carboplatin; lomustine; procarbazine; thioguanine; vincristine,6,124,846
etukg.QDmGNhEbcVYiC8ZEY47RBCtsXeGzma31kE92.g3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; isotretinoin; mesna; thiotepa; tretinoin; vincristine,14,142,243
etvc0KqlR8XA81gKcXBFj3CtGCBWUU5SogoziuZN0B.Y3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thalidomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",117,131,857
etvdRrG0KT11YzLY9cJfkN75s.SfA7DsBGPtbuVCsC-Y3,brigatinib,1,8,204
eu4JLxbJXyiJh4tqCT0oJrz9SxZ4yJXQ134OEVeDUCuA3,Cyclophosphamid; Cyclophosphamide; Leucovorin; Rituxan; filgrastim; methotrexate; pegfilgrastim; rituximab; vincristine,9,287,1044
euDlgzMpgwl-wpVJNYg8DRtqlWv9kbVNx1a6vQPg6Uak3,Cyclophosphamid; Cyclophosphamide; Ziextenzo; carboplatin; cisplatin; etoposide; filgrastim; pegfilgrastim; triamcinolone; vincristine,10,83,281
euFNCqiyNIFeV2M6QAsFXKTBFNdwkIrF.0ldTGaWriq43,cisplatin; lomustine; vincristine,3,38,230
euIpsLdL.OBiEgTTJnDswcO9-wSeaXS8oWri.WI93QRE3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; Avastin; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Lupron Depot; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temodar; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; Vinblastine Sulfate; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; leuprolide; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vinblastine; vorinostat",120,187,824
euLTn1Z8y-jbtgj8AThlmuKdyOFPMDdk958r4PtJJ4ew3,triamcinolone,1,1,0
euP7Qw30mvNN1saM0PuCvgFxRzsFbRHYJsoboCznz.H03,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Koselugo; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Matulane; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Progesterone; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Tabloid; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Zofran; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; selumetinib; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thioguanine; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",123,3203,4625
euQ7IMdK4DK3uDpBeE1wgQwjfjGH3wH6My.YE9-C0XZM3,Cyclophosphamid; Cyclophosphamide; cisplatin; lomustine; vincristine,5,96,383
euREXae1YEtiDE4CaUWMy63q9uWTBF7HDLHGEF7N6zms3,Testosterone Cypionate; triamcinolone,2,14,1554
euUx6LvXHH-G1P65RxdzJ0vx9HJMQVCPfpEDLoWkzkpg3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Progesterone; carboplatin; cisplatin; etoposide; filgrastim; isotretinoin; mesna; pegfilgrastim; thiotepa; tretinoin; vincristine,16,152,4708
euXdy82L95-sq-bYVNMfZ9qJq1E7bt0i-IKwzJsmOJ-Y3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; triamcinolone; vincristine,14,127,4447
euYhhA6xn3bG25z1dGZ0vNlNOrRe.NUezfkqUuh-FicU3,Zofran,1,1,0
euaxBFhMYH0w2I5bojeJXG5zxJHXA1dw7BMhPItJnrc83,carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,6,67,121
eucC2AEOg9-KJYhvgjPt6ESHke2UlukHdKXHZYhdcPv83,Cyclophosphamid; Cyclophosphamide; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; vincristine,8,47,162
euqCudmQ4ZTCdUfgFJwxmnJv9X-AKcWanyMysjheD3tc3,clofarabine; mercaptopurine; methotrexate; triamcinolone,4,28,1497
euqrZbCV-anh0EW5HneN7vZPihtRWtFz7tAA3udJmSmo3,Valproic Acid,1,1,0
eurfqNo8bjxI3kQHMq5bOGQ3,Cyclophosphamid; Cyclophosphamide; Hizentra; Rituxan; etoposide; filgrastim; mercaptopurine; mesna; methotrexate; methotrexate sodium; pegfilgrastim; rituximab; triamcinolone,13,114,3954
ev-VU-2gntrFKpVUb14J58K-thOpSC4L.wk4.ZmGMjQw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; Everolimus;;Dose; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; lomustine; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; procarbazine; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; thioguanine; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",119,1115,1451
evGODlWtiJ2-.M5mRpETO2Q3,Cyclophosphamid; Cyclophosphamide; G-CSF; Progesterone; cisplatin; etoposide; filgrastim; mesna; vincristine,9,107,1244
evJS2RqNmcewY0zF6KJNLdX0KkEItwfr3HDh-kzluEjg3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Leucovorin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; vincristine,12,108,251
evKOhA.TfhgSbpt-BUFlyssM.JyKRKvzyAPTPMN3-ZuU3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",110,2977,420
evPsvOlSoD-cFfz4AcG98gIuuK-W0PtyjxkC2j0j21WU3,Pemazyre; Progesterone; alpelisib; carboplatin; vincristine,5,8,931
evPwZziNuhqR.4JF2c9rXx50paTxrMZ1opwW09Y3EoB83,sirolimus; triamcinolone,2,23,2361
evWc9UKA275j5vnZPrCiFMX2Byg3Q9c1.xyKnuDtbfvk3,bevacizumab; carboplatin; vincristine,3,70,147
evhprmwBmiofWMDZRzFjeb9tENCRj.RicFYlVDAckUVQ3,imiquimod; triamcinolone,2,2,30
evsYRVvYoqBG6V5dotzCOww3,Valproic Acid; isotretinoin; tretinoin; zoledronic acid,4,7,1176
evxXMfctCl3cy4nBAsumhCB1FusOKeIGjRMg.adI9b2M3,Temozolomide capsule; cisplatin; irinotecan; lomustine; temozolomide; vincristine,6,247,1187
ew0QSW7XhyWpuf2wNcMlLKowp5O4Fzp6cWgsfTDSTx.o3,Cyclophosphamid; Cyclophosphamide; G-CSF; Glutamine; Investigational Chemotherapy (unspecified); Leucovorin; Neulasta; Temozolomide capsule; bevacizumab; carboplatin; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; ifosfamide; mesna; methotrexate; pegfilgrastim; plerixafor; tazemetostat; temozolomide; thiotepa; vincristine,26,416,2051
ewDd8ZzqnyOst4yvh-xUe6Rt8KJ7Z86EPhaf6MkTTHb83,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; Granix; Leucovorin; carboplatin; cisplatin; etoposide; filgrastim; mesna; methotrexate; pegfilgrastim; propranolol; thiotepa; vincristine,17,146,517
ewM12er2LNt8TyOigQBri-mcvdbhRC1QM0gi5NcCKGtw3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; Glutamine; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; plerixafor; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thiotepa; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",126,3979,2589
ewb74F6zeRrFMpNxtj5MQK.h4YyII.QBplLhfyweBRLY3,Dabrafenib Mesylate; Ketoconazole; Mekinist; Progesterone; Tafinlar; dabrafenib; trametinib,7,62,578
ewgRQREzkKTGeuLFPUKPL8T3IoNP597H.il4gm3QEaJk3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Emend; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; cytarabine; dactinomycin; dasatinib; dexrazoxane; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; methotrexate; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",123,454,211
ewj.Tv-ZTJiFhDyCJVVsLlTtMLGH-ZHzzwPb-Ji0l36k3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Temozolomide capsule; amifostine; bevacizumab; cisplatin; etoposide; filgrastim; irinotecan; isotretinoin; mesna; temozolomide; thalidomide; thiotepa; topotecan; tretinoin; vincristine,19,377,2078
ewno7iss2CXwTXlwolgQEMiWE2zXE4tkqjDHk2dm5d0s3,Temozolomide capsule; temozolomide,2,4,34
ex-mSzsv8p3DTs6ZQ2FpXEsR.pDuUGEEfboRP3TE7FOw3,Cyclophosphamid; Cyclophosphamide; cisplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; pegfilgrastim; temozolomide; triamcinolone; vincristine,12,118,217
ex19kk3diN4zlUfsCMLolxLUPLr9vOIhfG9XT8rdBF4c3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; cisplatin; cytarabine; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; methotrexate; pegfilgrastim; temozolomide; vincristine,14,280,475
ex54PvNc4ERBkN-j3DsFJKtlFcccuX2tHtaU.l6hKwWg3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; ATRA; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mekinist; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Vinblastin; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vinblastine; vincristine; vorinostat",116,1004,1763
ex8kekXPLK1coj.ARvZOOuWJ4Vep1rjWH-hu2c3LC0-03,Neulasta; Ziextenzo; clofarabine,3,22,148
exFIlV1YMxIhmjTQW4dZnDQ3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Lupron Depot; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Testosterone Cypionate; Thalomid; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Valproic Acid; Zofran; Zometa; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; cetuximab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; leuprolide; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thalidomide; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vorinostat",124,799,5553
exG.lWDVb3EZ73.5BrJHTmE2ToJDgeTJxbp9FG.1FN743,triamcinolone,1,2,0
exOe2.EF8DffMctyQ2dcAynIrwnnFzZggVBxvS0JIY4k3,Apatinib; Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; bevacizumab; carboplatin; etoposide; filgrastim; ifosfamide; lapatinib; lapatinib ditosylate; lomustine; mesna; pegfilgrastim; temozolomide; thalidomide; topotecan; vincristine,18,307,1384
exTpIWvCd3HAJsz-f.I-z3hAMrZmGKOCsXvmADnOfYIA3,Cyclophosphamid; Cyclophosphamide; Fulphila; Neulasta; Temozolomide capsule; cisplatin; etoposide; filgrastim; pegfilgrastim; temozolomide; vincristine,11,86,281
exXq1f7UJ1HVKmBlnMPP.mCYLmJqs7IEaarv7hCi1v0c3,carboplatin; vincristine,2,148,400
exmRIrFumwqNaPszz7EhuxqnzmrltvrLv21PPAUlK8wI3,anastrozole,1,1,0
extmfQ6mBcT7sAj5oBvPQ25LE60xDCvAacYjyBhB7GHU3,Cyclophosphamid; Cyclophosphamide; G-CSF; carboplatin; etoposide; filgrastim; mesna; triamcinolone; vincristine,9,58,2413
ey2lwan4G3Ge.xmIbIUSc5g3,letrozole,1,2,188
ey62cGrKsyVWuicS8sFBJpyRnb0jwcrCdiLZxqWrp4T43,Dabrafenib Mesylate; Temozolomide capsule; Valproic Acid; Vitrakvi; dabrafenib; larotrectinib; temozolomide; trametinib,8,43,471
eyA.eBxQ.PmUIKakqKsLmxB5qlvDCTZWFEjiHX5WhLeA3,Tabloid; bevacizumab; carboplatin; lomustine; procarbazine; thioguanine; vincristine,7,221,690
eyAH4ac0XV0IY.hBIqRh3BA3,Valproic Acid; isotretinoin; tretinoin,3,3,1440
eyFJejZSFOxfYNApSiwK2qkuWa7cuHWqrtnhQP8NxHtA3,doxorubicin; mercaptopurine; methotrexate; vincristine,4,119,338
eyLsFRJdGp9F89FwxmE1uDzg8x2tvea.S-X0MsaiJKZM3,Progesterone; Valproic Acid,2,2,631
eyMFTHsfd4RRWSR.UGdNgkNWys0L8Yv6x2N0G8KQrXWc3,Cyclophosphamid; Cyclophosphamide; Etopophos; G-CSF; Glutamine; Zarxio; Ziextenzo; carboplatin; etoposide; etoposide phosphate; filgrastim; gemcitabine; ifosfamide; mesna; oxaliplatin; paclitaxel; pegfilgrastim; plerixafor; thiotepa; tretinoin,20,161,537
eyNW9zWl3W2AOMfRcg1k6XnSfXV9ZC6QZ2Sign2RVtWU3,triamcinolone,1,2,22
eySYOVlcPY2eyjVIJRQLhT6giUGkGap9rJD4.IRyagmU3,Valproic Acid,1,2,0
eyX6Y7OTZOeReVQoewylQeONKHXReFJxWk.ZWTEzdJA03,Cyclophosphamid; Cyclophosphamide; G-CSF; Temozolomide capsule; Valproic Acid; bevacizumab; carboplatin; cisplatin; filgrastim; irinotecan; plerixafor; temozolomide; topotecan; vincristine,14,255,599
eymLKl.N1I6RwIK4GlzWttiIFBNfrrAOAcE9faWZ1-Lo3,Dabrafenib Mesylate; Lupron Depot; Mekinist; Tafinlar; carboplatin; dabrafenib; leuprolide; trametinib; vincristine,9,191,2555
eynDS-vDmqaeJsT-F0QAAGqqcMK4WC6QrOhid.4ydq8c3,triamcinolone,1,3,51
eynMz8inQbUnQEHMU761-PwA4yKzGFlBmjy9qvL2VFGk3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Glutamine; carboplatin; cisplatin; etoposide; filgrastim; mesna; pegfilgrastim; thiotepa; triamcinolone; vincristine,14,126,382
eyrlRs-R3nHX2d0GGWnwXTLPE9ygkne4TJ0JhiR91xWE3,Testosterone Cypionate,1,29,1140
eyrm76KMzQoczBpzeMeNiag3,Valproic Acid,1,2,22
eytfC9kuVaOK-sO36RYDmrwNHR14303qfWZ9XgiSqdEI3,Koselugo; selumetinib; triamcinolone,3,19,1873
eyvQQCZinnJZhrq3SdVktSA3,Cyclophosphamid; Cyclophosphamide; Temozolomide capsule; bevacizumab; etoposide; irinotecan; temozolomide; thalidomide; vincristine,9,74,361
eyvmUbTkfXxW7PCGa.2To7iQYPGOPz4pJ-ZyjguA1jyk3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Neulasta; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; Votrient; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dactinomycin; dasatinib; dexrazoxane; doxorubicin; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; ifosfamide; imatinib; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; irinotecan; larotrectinib; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pazopanib; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; sirolimus; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; topotecan; trametinib; trametinib dimethyl sulfoxide; two-drug chemotherapy group; vincristine; vorinostat",133,907,886
eyyF8hc3fgQRsZ2sGvRqxvJoSt1A0nt6XaiHUq23I9pc3,carboplatin; vincristine,2,146,441
eyyfkIvGjg.Qw38bKCJzsTmBicGnivPShgwJ5vUwHV3o3,Neulasta; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim; triamcinolone,8,51,300
ez06aoF4XVSkwmJldvLzVLLVcCJVpwZqJF8bgz.RIcXg3,Cyclophosphamid; Cyclophosphamide; G-CSF; GM-CSF; Neupogen; Temozolomide capsule; carboplatin; dactinomycin; dexrazoxane; doxorubicin; etoposide; filgrastim; gemcitabine; ifosfamide; irinotecan; mesna; paclitaxel; pegfilgrastim; temozolomide; topotecan; vincristine,21,169,311
ez2LBt6GH5wS-TgcXJo8OJQYq80801OJ87gedC7ySAOw3,carboplatin; vincristine,2,146,399
ezBbsrh1aShnW0HdsvKLwqTDvbAfrBmgDk9T0sn5LNp83,etoposide; triamcinolone,2,9,98
ezJ8tJjBUYu1P-viK.YGoak9NK5bEjuL2nDfUSqkm8ZY3,carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,6,82,110
ezPaCBxVA0tArp9AkEqijXxy7HJ4C2W5SNkhb2IrQbtM3,Valproic Acid; tretinoin,2,5,4629
ezSuDKhxVrcmVb5uL6OK8IC3mFRaqq-kIlS8pSq04KPg3,G-CSF; GM-CSF; carboplatin; etoposide; filgrastim; ifosfamide; mesna; pegfilgrastim,8,66,154
ezbY9f2Dv.vWLMADPFoNFdz90uKb52yD-CT.XYqH6Cmg3,Cyclophosphamid; Cyclophosphamide; G-CSF; Progesterone; cisplatin; filgrastim; mesna; pegfilgrastim; plerixafor; vincristine,10,104,203
ezeNgm9yqZlMRFRCL1fyvA2DXBW4-FvkUYzrqxeNm2BI3,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; Ketoconazole; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Temozolomide capsule; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin paclitaxel bevacizumab; chlorambucil drug; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; everolimus; fenretinide lipid matrix; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; temozolomide; trametinib; trametinib dimethyl sulfoxide; triamcinolone; two-drug chemotherapy group; vorinostat",114,1335,246
ezfuLQYDMMaTyIqs7Wd8Ulp1np4sK24Q3Wbpbdl5mSUQ3,ATRA; Valproic Acid,2,7,1408
ezjWw7PM8imN-KkF7NXqWbtY1Nk.lh8n.SAfUbqdLWPI3,Ketoconazole; Temozolomide capsule; bevacizumab; cabozantinib; cabozantinib s-malate; lomustine; selumetinib; temozolomide,8,114,797
ezpOvGgYvKbS4K16bs4TTLA3,Testosterone Cypionate; imiquimod,2,6,3708
ezsBlpPnV0ZTVXe4ADMwv0h242I1YZZ25KFR4cKwNJx43,"***; 131-MIBG + Vorinostat; 1A46 Drug Substance; AMG386 and bevacizumab; AZD1775; AZD6244; Access to Experimental Drugs; Adjuvant Atezolizumab-Bevacizumab Therapy; Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy; Anti-PD-1 Drugs; Antibody-Drug Conjugates; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; Bevacizumab Avastin; Bevacizumab, Everolimus and LBH589; Bevacizumab-IRDye800CW; Bortezomib drug; CUDC-907; Cemiplimab REGN2810; Chemo with concomitant Capecitabine and KD018; Combination drug; Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab; Combination, Rogaratinib + palbociclib + fulvestrant; Cyclophosphamid; Cyclophosphamide; DFMO; DIFLUOROMETHYLORNITHINE; DS-8273a + nivolumab; Dabrafenib and trametinib combination; Drug-based intervention; Drugs Approved for Childhood Cancers; Drugs Approved for Conditions Related to Cancer; Drugs Approved for Different Types of Cancer; ETBX-071 PSA-based Oncolytic Virus; Enzalutamide,, soft capsules, once daily; Everolimus Afinitor tablets; FOLFIRI-BEVACIZUMAB; Fenretinide; Fimepinostat; G-CSF; GM-CSF; Glutamine; IV FOLFIRI+ target agent bevacizumab or cetuximab every 2 weeks; Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab; Indoximod; Investigational Chemotherapy (unspecified); Ipilimumab -/kg; LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide; LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; MK-1775; Mocetinostat Induction Phase + Ipilimumab + Nivolumab; Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab; Nivolumab & Ipilimumab; Nivolumab -/kg; Nivolumab Protocol; Nivolumab and Hyaluronidase-nvhy; Nivolumab and Relatlimab-rmbw; Nivolumab induction; Nivolumab maintenance; Nivolumab with chemoradiation; Nivolumab-relatlimab FDC; ONC201; ONO-7475 once daily; Oncaspar; Oncolytic virus VRT106; PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001; PTC596; Palbociclib100mg; Palbociclib125mg; Pemetrexed and Gemcitabine plus Bevacizumab; Placebo - Concentrate; Recombinant oncolytic herpes simplex virus type Ⅰ R130; Relatlimab FDC + Nivolumab; SAHA(Suberoylanilide; SAHA-Suberoylanilide; SAHA/Vorinostat; Serplulimab combined with bevacizumab and first-line chemotherapy; Surufatinib; Surufatinib and Serplulimab; Surufatinib plus chemotherapy; TAK-580; Three-drug chemotherapy group; Trametinib placebo; Trastuzumab+Nivolumab+Gemcitabine+Cisplatin; Trifluridine/tipiracil + bevacizumab; albumin-bound paclitaxe combined with bevacizumab biosimilar; bevacizumab; capecitabine, oxaliplatin, irinotecan and bevacizumab; carboplatin; carboplatin paclitaxel bevacizumab; chlorambucil drug; cisplatin; concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME; concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX; dasatinib; epirubicin - cyclophosphamide / docetaxel + bevacizumab; etoposide; everolimus; fenretinide lipid matrix; filgrastim; intra-arterial oxaliplatin + Systemic FOLFIRI + target agent bevacizumab or cetuximab every 2 weeks; ipilimumab; isotretinoin; loncastuximab tesirine; loncastuximab tesirine-lpyl; mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody; mesna; nivolumab; ntifier:ADVL0921; once daily for two consecutive days Picato; paclitaxel + everolimus RAD001; palbociclib; palbociclib isethionate; pegfilgrastim; rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim; selinexor; standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001; tazemetostat; tazemetostat hydrobromide; thiotepa; trametinib; trametinib dimethyl sulfoxide; tretinoin; triamcinolone; two-drug chemotherapy group; vincristine; vorinostat",126,2542,636
ezsmxcBc2NUw2qRHIkLf15xHH95iF58m4F6SQPAegX.c3,ATRA,1,1,0
